No retraction, correction or concern found when last checked on Oct 19, 2026.

Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

Laura C Price, Stephen J Wort, Simon J Finney and 2 more

Critical Care · 2010 · Systematic review · CC BY

Abstract

Introduction. Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting right ventricular (RV) failure occur in many critical illnesses and may be associated with a worse prognosis. PH and RV failure may be difficult to manage: principles include maintenance of appropriate RV preload, augmentation of RV function, and reduction of RV afterload by lowering pulmonary vascular resistance (PVR). We therefore provide a detailed update on the management of PH and RV failure in adult critical care.

Methods. A systematic review was performed, based on a search of the literature from 1980 to 2010, by using prespecified search terms. Relevant studies were subjected to analysis based on the GRADE method.

Results. Clinical studies of intensive care management of pulmonary vascular dysfunction were identified, describing volume therapy, vasopressors, sympathetic inotropes, inodilators, levosimendan, pulmonary vasodilators, and mechanical devices. The following GRADE recommendations (evidence level) are made in patients with pulmonary vascular dysfunction: 1) A weak recommendation (very-low-quality evidence) is made that close monitoring of the RV is advised as volume loading may worsen RV performance; 2) A weak recommendation (low-quality evidence) is made that low-dose norepinephrine is an effective pressor in these patients; and that 3) low-dose vasopressin may be useful to manage patients with resistant vasodilatory shock. 4) A weak recommendation (low-moderate quality evidence) is made that low-dose dobutamine improves RV function in pulmonary vascular dysfunction. 5) A strong recommendation (moderate-quality evidence) is made that phosphodiesterase type III inhibitors reduce PVR and improve RV function, although hypotension is frequent. 6) A weak recommendation (low-quality evidence) is made that levosimendan may be useful for short-term improvements in RV performance. 7) A strong recommendation (moderate-quality evidence) is made that pulmonary vasodilators reduce PVR and improve RV function, notably in pulmonary vascular dysfunction after cardiac surgery, and that the side-effect profile is reduced by using inhaled rather than systemic agents. 8) A weak recommendation (very-low-quality evidence) is made that mechanical therapies may be useful rescue therapies in some settings of pulmonary vascular dysfunction awaiting definitive therapy.

Conclusions. This systematic review highlights that although some recommendations can be made to guide the critical care management of pulmonary vascular and right ventricular dysfunction, within the limitations of this review and the GRADE methodology, the quality of the evidence base is generally low, and further high-quality research is needed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Pulmonary vascular dysfunction is a broad term and may be central to several disease processes in the intensive care unit (ICU). Components include pulmonary endothelial dysfunction, altered lung microvascular permeability, vasoactive mediator imbalance, abnormal hypoxic vasoconstriction, pulmonary metabolic failure, microvascular thrombosis, and later, vascular remodelling. The resulting elevation in pulmonary vascular resistance (PVR) and pulmonary hypertension (PH) may increase the transpulmonary gradient, and the right ventricular "pressure overload" can in turn result in right ventricular (RV) dysfunction and failure. RV dysfunction may also result from volume overload or a primary RV pathology reducing contractility, including RV infarction and sepsis (Table 1).

2PH is defined at right-heart catheterization in the outpatient setting, with resting mPAP exceeding 25 mm Hg, and a PVR greater than 240 dyn.s.cm-5 (3 Wood units). At echocardiography, the presence of PH is suggested by the estimated RV systolic pressure (RVSP) exceeding 35 mm Hg (being severe if >50 mm Hg) (see later), and the pulmonary arterial acceleration time (PAT) may be shortened. Pulmonary arterial hypertension (PAH) defines PH not due to left-heart disease, with PAOP <15 mm Hg or without echocardiographic evidence of increased left atrial pressure. The severity of PH may depend on the chronicity: the actual pulmonary artery pressure generated will increase with time as the RV hypertrophies.

3RV dysfunction describes reduced RV contractility, which may be detected in several ways. At echocardiography, RV distention causes the intraventricular septum to deviate, with resulting paradoxic septal movement that impinges on LV function. RV function may be difficult to assess on echocardiography, especially in ventilated patients, and measurement of the descent of the RV base toward the apex (tricuspid annular systolic excursion, TAPSE) or RV fractional shortening may useful. Invasive monitoring may show a CVP exceeding the PAOP, or increasing CVP and PVR with a decreasing cardiac output (and mPAP may therefore decrease), and high right ventricular end-diastolic filling pressure is characteristic. By using an RV ejection fraction (RVEF) PAC, an increase in RV end-diastolic index and a reduction in RVEF are seen. We have defined RV failure to be the clinical result of RV dysfunction with the onset of hypotension or any resulting end-organ (for example, renal, liver, or gastrointestinal) dysfunction. Acute cor pulmonale (ACP) refers to acute right heart failure in the setting of acutely elevated PVR due to pulmonary disease.

4Pulmonary hypertension per se is frequently encountered in the ICU. It is commonly due to elevated pulmonary venous pressure in the setting of left-sided heart disease, or in patients with preexisting pulmonary vascular disease. It is well recognized after cardiothoracic surgery, in part related to the endothelial dysfunction seen with cardiopulmonary bypass (CPB). PH is also associated with sepsis; acute respiratory distress syndrome (ARDS) (with associated acute RV failure in 10% to 25% of cases), and in up to 60% of patients after massive pulmonary embolism (PE). PH is important to recognize in the ICU because its presence predicts increased mortality in these conditions as well as after surgical procedures. Mortality from cardiogenic shock due to RV infarction (> 50%) exceeds that due to LV disease. We therefore thought that a systematic review of the current evidence for the management of PH, resulting RV dysfunction, and failure in adult patients in the ICU, would be a useful addition to the critical care literature.

The pulmonary circulation and pathophysiology of right ventricular failure

5The normal pulmonary circulation is a high-flow, low-pressure system. Unlike the left ventricle (LV), the thin-walled right ventricle tolerates poorly acute increases in afterload. This may lead to acute distention (Figure 1), with a resulting increase in oxygen consumption and reduction in contractility. The dilated RV, together with paradoxic intraventricular septal movement, lead to reduced LV filling, cardiac output (CO), and oxygen delivery. The principle of ventricular interdependence is important in most settings: superficial myocardial fibers encircle both ventricles; thus they are contained within the same pericardial cavity (except maybe after cardiac surgery), as well as sharing a septum, effectively existing "in series". This explains the decrease in LV output seen during positive-pressure ventilation and why RV pressure and volume overload cause diastolic dysfunction of the LV. Furthermore, because of the RV/LV interactions, the LV may markedly depend on atrial contraction for filling and may tolerate atrial fibrillation and vasodilating therapy particularly poorly.

6In addition, perfusion of the right coronary artery is usually dependent on a pressure gradient between the aorta and the right ventricle, which, in the setting of increased RV afterload and decreased coronary blood flow, may lead to RV ischemia, with further severe hemodynamic decompensation (Figure 2). In acute-on-chronic RV-pressure overload, the already-hypertrophied RV tolerates much higher pressures before decompensation, although the ability of the RV to augment CO in chronic PH may be restricted by its relatively "fixed" afterload. In any setting, the most common cause of increased RV afterload is an increase in PVR (Table 2).

7The gold standard for the diagnosis and management of PH and RV dysfunction in the ICU setting is considered by some to be through pulmonary artery catheterization (PAC), even though most of the information can be obtained noninvasively by echocardiography: the requirement for PAC in this population remains controversial. It must, however, be acknowledged that it provides the only direct continuous measurement of right-sided pressures and direct measurement of RV afterload, whereby, through measurement of cardiac output, pulmonary pressures and the pulmonary artery occlusion pressure (PAOP, the "wedge"), the PVR can be calculated (Figure 3). Overall outcomes are not improved when the PAC is used in general in critically ill patients; and complications do occur: the use in general is therefore declining. However, no studies have been done in the "pulmonary vascular" subpopulation. Alternative invasive hemodynamic measurements, such as CVP, may be useful surrogates for volume status in RV failure, by using the diastolic component of the CVP. Importantly, when monitoring CVP in patients with significant tricuspid regurgitation (TR), the variable V wave may be misleading, as it is included in the mean CVP calculation on most automated machines, and if rising, indicates RV overdistention. In the setting of cardiac surgery, one study shows that PAC use has reduced from 100% to 9% from 1997 to 2001, thought to reflect increased use of transesophageal echocardiography (TEE). In the setting of cardiac surgery, PAC may remain indicated for patients with PH and low CO and those predicted to have a difficult postoperative course, when a Swan introducer sheath may be inserted preemptively, or inserted for continuous monitoring after a diagnosis of RV dysfunction made with echocardiography. PAC is also a useful cardiac monitor with intraaortic balloon counterpulsation. Few data exist on PAC in other settings of pulmonary vascular dysfunction in the ICU, but one study suggests that PVR may be a poor indicator of pulmonary-circulation status in ventilated patients with ALI/ARDS. The role of echocardiography, both transthoracic (TTE) and TEE, is increasingly recognized in assessing RV function in many ICU settings and provides essential information about RV geometry and function. PA pressures may be assessed by estimating the systolic-pressure gradient across the tricuspid valve by using the modified Bernoulli equation, and although the correlation between invasive and sonographic measurement has been shown to be excellent in these studies, no studies have correlated PAC with echocardiographic measurements in the ICU population. In reality, a combination of invasive and noninvasive techniques is used. Biomarkers such as brain natriuretic peptide (BNP) are useful in monitoring chronic PAH, in risk-stratifying acute pulmonary embolism (see later), and in identifying ARDS-related pulmonary vascular dysfunction, although their role is less clear in other ICU settings.

8The diagnosis and management of acute pulmonary embolism (PE) warrants a specific mention, as it is a relatively common cause of acute RV failure in the ICU. Available therapies include thrombolysis and embolectomy, reducing the clot burden and acute mortality, as well as reducing the longer-term risk of chronic thromboembolic PH. Given that more than half of related deaths occur within an hour of the onset of symptoms, effective supportive treatment of shock is paramount. Patients presenting with acute PE are risk stratified according to the effects of elevated RV afterload: hypotensive patients and those with elevated cardiac biomarkers or echocardiographic indices of RV strain, or both, are deemed at increased risk, and thrombolysis is indicated.

9The management of PH and RV dysfunction in the ICU is challenging. No agreed algorithms exist, although treatment should aim to prevent pulmonary hypertensive crises and acute cor pulmonale. These comprise the spectrum of acute pulmonary vascular dysfunction and may result in cardiovascular collapse due to resulting biventricular failure. Management principles include the following: 1) optimization of RV preload, 2) optimization of RV systolic function, 3) reduction of afterload by reduction of increased PVR, and 4) maintenance of aortic root pressure to ensure sufficient right coronary artery filling pressure (Table 3).

Systematic review of ICU management of pulmonary vascular and RV dysfunction

10We performed a systematic review of the literature over the period from 1980 to 2010, by using set search terms, and the electronic database of the US National Library of Medicine and National Institute of Health (PubMed). After initial identification, abstracts were reviewed for relevance, and appropriate studies were included in the review. Reference lists of relevant articles were hand-searched for further studies and reports. The search was limited to publications in English. Studies were deemed suitable for inclusion according to the criteria listed and where the patient population and study design was defined; and the outcomes were limited to those depending on the specific GRADE question (see Additional file 1). The breakdown of articles obtained by the systematic search is shown (Table 4). After identification, relevant studies were included and subjected to a GRADE analysis to see whether we could make specific management recommendations.

ICU management of pulmonary vascular and RV dysfunction

11Management of PH with associated RV dysfunction in the ICU setting can be broken down into several treatment goals (Table 3). The first is to ensure adequate but not excessive RV filling or preload in the context of sufficient systemic blood pressure. The second goal is to maximize RV myocardial function, whether with inotropic support, rate or rhythm management, atrioventricular synchronization, or by using mechanical devices. The third is to offload the right ventricle by reducing the PVR with pulmonary vasodilators as well as by ensuring adequate oxygenation, avoiding hypercapnia and acidosis, and by minimizing mechanical compression of pulmonary vessels (for example, due to excessive airway plateau pressure). The fourth is to maintain adequate aortic root pressure to allow sufficient right coronary arterial perfusion.

Management of volume and use of vasopressors

12Systemic hypotension may relate to sepsis, overdiuresis, or progression of RV failure itself. Principles of volume management and vasopressor use are summarized.

Volume management

13With a normal RV, RV ejection fraction is usually primarily dependent on RV preload. In the setting of excessive myocardial distention (by fluids), wall tension increases according to the Frank-Starling mechanism, and muscle fiber length is increased, beyond a certain point at which ventricular function will fail. This situation may be precipitated sooner in the setting of PH and RV dysfunction, in which both hypo- and hypervolemia may reduce cardiac output. In stable patients with PAH, high plasma volumes are associated with worse outcomes, but very few clinical studies have been performed in pulmonary vascular dysfunction, and the use of fluid loading remains controversial. Some animal studies show that fluids increase the cardiac index; others show that they worsen shock by inducing RV ischemia or decreasing LV filling or both as the result of ventricular diastolic interdependence (due to an increase in RV volume).

14In acute cor pulmonale after massive PE, increased filling may be at least initially required. In observational studies in sepsis, up to 40% of patients have evidence of RV failure, predominantly due to primary RV dysfunction. These patients have a higher CVP at baseline and are unable to augment stroke volume or perfusion pressure with fluid challenges alone, and so usually also require catecholamines.

15RV volume overload is a very important principle to recognize and treat promptly in RV failure. It may be identified by a rising V wave on the CVP trace, or by increased TR due to RV overdistention seen at echocardiography. In this situation of "backwards" heart failure, no further escalation of vasoactive agents is likely to be helpful (and may even be harmful), and management involves fluid removal (by using diuresis or hemofiltration) and avoidance of excessive RV afterload. Unmonitored fluid challenges are inadvisable in any setting of RV failure.

GRADE RECOMMENDATION 1

16Based on overall very-low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Close monitoring of fluid status according to effects on RV function is recommended. Initial carefully monitored limited volume loading may be useful after acute PE, but may also worsen RV performance in some patients with pulmonary vascular dysfunction, and vasoactive agents may be required.

Vasopressors

17An essential goal is to maintain systemic blood pressure above pulmonary arterial pressures, thereby preserving right coronary blood flow: unlike left coronary artery perfusion, which occurs only during diastole (as aortic pressure exceeds LV pressure only during this period), perfusion of the right coronary artery usually occurs throughout the cardiac cycle, dominating in systole. It is understood that, as PVR approaches SVR, coronary perfusion will decrease, and if PVR exceeds SVR, coronary filling will occur only in diastole. By augmenting aortic root pressure by using vasopressors in the setting of increased RV afterload, RV ischemia can therefore be reversed. Vasopressors will, however, inevitably have direct effects on the pulmonary circulation as well as myocardial effects (Table 5).

Sympathomimetic pressors

18These include the catecholaminergic pressor, norepinephrine, and the noncatecholaminergic pressor phenylephrine. Their complex effects on the pulmonary circulation depend on the dose-related relative α- and β-adrenoreceptor stimulation as well as the degree and nature of RV dysfunction. All may potentially lead to tachydysrhythmias, diastolic dysfunction, myocardial ischemia, hyperlactatemia, and hypercoagulability.

Norepinephrine

19Norepinephrine (NE) exerts its systemic vasopressor effects through α-1 agonism. Activation of these receptors also causes pulmonary vasoconstriction, although the potential adverse effects on PVR are likely to occur only at high doses. Most evidence supporting this comes from animal studies in models of pulmonary vascular dysfunction, with NE at doses less than 0.5 μg/kg/min not increasing PVR. In persistent PH of the newborn, low-dose NE (0.5 μg/kg/min) reduces the PVR/SVR ratio. In adults with septic shock, higher doses of NE increase PVR/SVR, although without worsening RV performance. In patients with sepsis, PH, and associated RV dysfunction, NE increases SVR and improves the RV oxygen supply/demand ratio, although it does not increase RVEF and does increase PVR. Importantly, NE is positively inotropic through β-1 receptor agonism, thus improving RV/pulmonary arterial coupling, CO, and RV performance in studies of acute RV dysfunction due to PH, illustrated in a case report of acute PH after MVR surgery. In patients with chronic PH, NE reduces the PVR/SVR ratio, although it may not improve CI, which may relate to the "fixed" elevation in PVR.

Phenylephrine

20Phenylephrine (PHE) is a direct α-agonist. Its use improves right coronary perfusion in RV failure without causing tachycardia, although this benefit may be offset by worsening RV function due to increased PVR.

GRADE RECOMMENDATION 2

21Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: NE may be an effective systemic pressor in patients with acute RV dysfunction and RV failure, as it improves RV function both by improving SVR and by increasing CO, despite potential increases in PVR at higher doses.

Nonsympathomimetic pressors: Vasopressin

22Arginine vasopressin (AVP) causes systemic vasoconstriction via the vasopressinergic (V1) receptor. Experimental studies have revealed vasodilating properties at low doses that include pulmonary vasodilatation through an NO-dependent mechanism via V1 receptors. This property manifests clinically as a reduction in PVR and PVR/SVR ratio. AVP has also been used as a rescue therapy in patients during PH crises, in which untreated equalization of systemic and pulmonary pressures may be rapidly fatal. At low doses (0.03-0.067 U/min), it has been used safely in sepsis, as well as in patients with acute PH and RV failure with hypotension after cardiac surgery and hypotension associated with chronic PH in several settings.

23AVP leads to a diuretic effect in vasodilatory shock, reduces the heart rate, and induces fewer tachyarrhythmias in comparison to NE. However, bradycardia may be encountered at high clinical doses. AVP may cause dose-related adverse myocardial effects at infusion rates exceeding 0.4 U/min, or even above 0.08 U/min in cardiogenic shock, which probably relate to direct myocardial effects, including coronary vasoconstriction.

GRADE RECOMMENDATION 3

24Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: In patients with vasodilatory shock and pulmonary vascular dysfunction, low-dose AVP may be useful in difficult cases that are resistant to usual treatments, including norepinephrine.

Inotropic augmentation of RV myocardial function

25The next major goal is to improve RV myocardial function by using inotropes. The use of mechanical support is discussed later. For sympathomimetic agents, desirable cardiac β1 effects at lower doses maybe offset by chronotropic effects precipitating tachyarrhythmias, as well as worsening pulmonary vasoconstriction at higher doses through α-agonism. Systemic hypotension may result from these agents and with phosphodiesterase inhibitors, which may necessitate co-administration of vasopressors.

Sympathomimetic inotropes

26Few clinical studies of these agents have been done in patients with PH and RV dysfunction. Dopamine increases CO, although it may cause a mild tachycardia in patients with PH and increase the PVR/SVR ratio. Dopamine also tends to increase the heart rate and to have less-favorable hemodynamic effects in patients with cardiomyopathy than dobutamine, although it does not increase PVR at doses up to 10 μg/kg/min in animals with pulmonary vascular dysfunction. In patients with septic shock, PH, and RV dysfunction, dopamine improves CI without an increase in PVR. In the recent large randomized controlled study comparing dopamine with norepinephrine in patients with septic shock, dopamine increased arrhythmic events and, in patients with cardiogenic shock, increased the risk of death. In patients with primary RV dysfunction (without PH) due to septic shock, epinephrine improves RV contractility despite an 11% increase in mPAP. In animal studies, epinephrine reduces the PVR/SVR more than does dopamine. Isoproterenol has been used in RV failure primarily as a chronotrope after cardiac transplantation, although it may induce arrhythmias.

Dobutamine

27At clinical doses up to 5 μg/kg/min in heart failure, dobutamine increases myocardial contractility, reduces PVR and SVR, and induces less tachycardia than does dopamine. It improves RV performance in patients with PH at liver transplantation, after RV infarction, and is used in PAH exacerbations. It is synergistic with NO in patients with PH. Experimentally, dobutamine has favorable pulmonary vascular effects at lower doses, although it leads to increased PVR, tachycardia, and systemic hypotension at doses exceeding 10 μg/kg/min. Given the adverse effects of systemic hypotension in these patients, it is important to anticipate and treat it with vasopressors when using dobutamine.

Inodilators

28An inodilator increases myocardial contractility while simultaneously causing systemic and pulmonary vasodilatation. Inodilators include the phosphodiesterase (PDE) III inhibitors and levosimendan.

PDE3 inhibitors

29Several types of PDE are recognized: PDEIII usually deactivates intracellular cyclic adenosine monophosphate (cAMP), and PDE3 inhibitors therefore increase cAMP and augment myocardial contractility while dilating the vasculature. The selective PDEIII inhibitors include enoximone, milrinone, and amrinone. They are most suited to short-term use because of tachyphylaxis, and mild tachycardia is common. Milrinone is most frequently used and has been shown to reduce pulmonary pressures and augment RV function in many studies in patients with pulmonary vascular dysfunction. Enoximone improves RV function in pulmonary vascular dysfunction after cardiac surgery and in patients with decompensated chronic obstructive pulmonary disease (COPD). Enoximone leads to fewer postoperative myocardial infarctions than does dobutamine, which may relate to the resulting improved gas exchange when compared with dobutamine and GTN. Concerns regarding platelet aggregation with amrinone do not appear to arise with enoximone or milrinone after cardiac surgery. As with dobutamine, resulting reversible systemic hypotension means that coadministration with pressors is often necessary. Agents such as norepinephrine, phenylephrine or vasopressin are used, with the latter reducing PVR/SVR more than norepinephrine. PDEIII inhibitors may also improve RV function in chronic PH.

30Nebulized milrinone is increasingly used to manage PH crises in several settings. Through pulmonary selectivity, it results in less systemic hypotension and less V/Q mismatch compared with intravenous use in patients with PH after mitral valve replacement surgery. The combination of milrinone-AVP reduces PVR/SVR and may be preferable to milrinone-NE in RV dysfunction.

Levosimendan

31Levosimendan sensitizes troponin-C to calcium and selectively inhibits PDE III, improving diastolic function and myocardial contractility without increasing oxygen consumption. It also acts as a vasodilator through calcium desensitization, potassium channel opening, and PDEIII inhibition. Levosimendan leads to a rapid improvement in hemodynamics, including reduction in PVR in patients with decompensated heart failure, with significant benefit on RV efficiency, with effects lasting several days. Levosimendan improves RV-PA coupling in experimental acute RV failure more than dobutamine. These effects have been shown clinically with improvements in RV function and reduction in PVR in ischemic RV failure, ARDS, and after mitral valve replacement surgery. In chronic PH, repetitive doses reduce mPAP and PVR from baseline and improve SvO2.

GRADE RECOMMENDATION 4

32Based on low-moderate-quality evidence (see Additional file 1), a WEAK recommendation can be made that low-dose dobutamine (up to 10 μg/kg/min) improves RV function and may be useful in patients with pulmonary vascular dysfunction, although it may reduce SVR. Dopamine may increase tachyarrhythmias and is not recommended in the setting of cardiogenic shock (STRONG recommendation based on high-quality evidence level).

GRADE RECOMMENDATION 5

33Based on mostly moderate-quality evidence (see Additional file 1), a STRONG recommendation can be made that PDE III inhibitors improve RV performance and reduce PVR in patients with acute pulmonary vascular dysfunction, although systemic hypotension is common, usually requiring coadmininstration of pressors. Based on low-quality evidence (see Additional file 1), a WEAK recommendation can be made that inhaled milrinone may be useful to minimize systemic hypotension and V/Q mismatch in pulmonary vascular dysfunction.

GRADE RECOMMENDATION 6

34Based on mostly low-quality evidence (see Additional file 1), a WEAK recommendation can be made that levosimendan may be considered for short-term improvements in RV performance in patients with biventricular heart failure.

Reduction of right ventricular afterload

35Physiologic coupling between the RV and the pulmonary circulation is a vital form of autoregulation of pulmonary circulatory flow (Figure 2). The RV is even less tolerant of acute changes in afterload than the LV, presumably because of the lower myocardial muscle mass. In sepsis, a reduction in PVR will increase the RV ejection fraction at no additional cost to cardiac output, but at levels beyond moderate PH, LV filling may be reduced, and ultimately cardiac output will decrease. Measures to reduce RV afterload may be nonpharmacologic (Table 3) or pharmacologic (Table 6).

Pulmonary vasodilator therapy

36Specific pulmonary vasodilators may be useful both to reduce RV afterload and to manipulate hypoxic vasoconstriction in patients with severe hypoxia. Agents are classically subdivided according to their action on the cyclic GMP, prostacyclin, or endothelin pathways. In the nonacute setting, these agents also target remodeling of"resistance" pulmonary vessels and have revolutionized the care of patients with PAH. Importantly, however, the management with pulmonary vasodilators in chronic PH patients differs in several ways from that with acute pulmonary vascular dysfunction, notably in terms of rapid changes in RV volume status, and potential adverse hemodynamic effects of nonselective pulmonary vasodilators in unstable patients.

37Pulmonary vasodilators should be used after optimization of RV perfusion and CO. Systemic administration of pulmonary vasodilators may reduce systemic blood pressure, potentially reducing RV preload and worsening RV ischemia. Exclusion of a fixed elevated pulmonary venous pressure is important, as increased transpulmonary flow may precipitate pulmonary edema. Furthermore, nonselective actions of vasodilators may result in worsening ventilation/perfusion (V/Q) matching. This risk is reduced with the use of inhaled pulmonary vasodilators, with which the agent will reach vessels in only ventilated lung units.

Adenosine

38Adenosine increases intracellular cAMP via A2 receptor agonism, and when administered intravenously, acts as a potent selective pulmonary vasodilator because of its rapid endothelial metabolism. It has been used as a therapy for adult PH in some settings, including after cardiac surgery, but may elevate LV end-diastolic pressure and cause bradycardia and bronchospasm. It is currently therefore recommended as an alternative to NO and prostacyclin in dynamic vasoreactivity studies rather than as treatment for PH.

Inhaled nitric oxide

39Inhaled nitric oxide (NO) is a potent pulmonary vasodilator with a short half-life due to rapid inactivation by hemoglobin. This minimizes systemic vasodilatation, although it necessitates continuous delivery into the ventilator circuit. NO selectively reduces PVR and improves CO in PAH, secondary PH, acute PE, ischemic RV dysfunction, and postsurgical PH. NO also improves oxygenation, RVEF, and reduces vasopressor requirements in PH after cardiac surgery, especially in patients with higher baseline PVR, with no augmented effect seen at doses above 10 ppm in these patients. Use of NO (or inhaled PGI2) after mitral valve replacement surgery results in easier weaning from cardiopulmonary bypass and shorter ICU stays.

40NO has been shown to reduce PVR and improve CO in several studies in patients with acute RV failure due to ARDS and to improve oxygenation at lower doses than the RV effects. Administration of NO does need to be continuous for PVR reduction, and a potential exists for worsening oxygenation at excessive doses. The reduction in RV afterload, however, does not correlate with clinical-outcome benefits. Similarly, despite short-term improvements in oxygenation in ARDS, no studies show a survival benefit.

41NO provides synergistic pulmonary vasodilatation with intravenous prostacyclin, inhaled iloprost, and oral sildenafil. Limitations include accumulation of toxic metabolites, although this is not usually a clinically significant problem. Rebound PH with RV dysfunction may occur after weaning from NO, which may be reduced with PDE5 inhibitors.

Prostanoids

42Prostanoids include prostaglandin-I2 (prostacyclin, PGI2) and its analogues, (iloprost) and prostaglandin-E1 (alprostadil, PGE1). An important difference between their formulations is their resulting half-life (Table 6). Prostacyclin is a potent systemic and pulmonary vasodilator, with antiplatelet and antiproliferative effects. In PAH, these agents reduce PVR, increase CO, and improve clinical outcomes, and are used in patients with NYHA III-IV symptoms.

43The use of prostanoids is most commonly described in ICU after cardiac surgery or transplantation. Intravenous prostacyclin, PGE1, inhaled prostacyclin, and iloprost all reduce PVR and improve RV performance in these settings, with inhaled agents being most selective. Intravenous PGE1 may cause marked desaturation in patients with lung disease. Inhaled prostacyclin has short-term equivalence to NO, and inhaled iloprost has been shown to be even more effective than NO at acutely reducing PVR and augmenting CO in PH after CPB and in PAH. Inhaled PGI2 also acutely improves pulmonary hemodynamics after acute massive PE. Although PGI2 impairs platelet aggregation, clinical bleeding was not increased in one study. The potential anticoagulant effect should be remembered, however, especially in patients after surgery and receiving concomitant heparin.

44In ARDS, intravenous prostacyclin reduces PVR and improves RV function, although it may increase intrapulmonary shunt. Inhaled prostacyclin and inhaled PGE1 improve oxygenation and reduce PVR in ARDS, with minimal effects on SVR. NO and intravenous PGI2 have been combined in ARDS with effective reduction of PVR without adverse effects.

PDE5 inhibitors

45PDE5 inhibitors, including sildenafil and vardenafil, increase downstream cGMP signaling, potentiating the beneficial effects of NO (Figure 4). PDE5 inhibitors acutely reduce PVR, and increase CO and reduce PAOP more than does NO. These agents improve clinical end-points in PAH, where endothelial NO is reduced and PDE5 expression is upregulated. PDE5 inhibitor may also exert milrinone-like effects through PDEIII inhibition, augmenting RV function. Despite their relative pulmonary selectivity and rapid onset, however, adverse effects may include reduced SVR with potential effects on RV performance. Oral sildenafil has been used to reduce PVR effectively in well-selected patients with PH after cardiac surgery without reducing the SVR. Even a single dose may facilitate weaning from NO, also without reducing SVR. Sildenafil may also improve myocardial perfusion and reduce platelet activation as well as endothelial dysfunction after CPB. Oral sildenafil has been effective in patients with PH due to left ventricular systolic dysfunction, reducing PVR and increasing CO, although reducing the SVR. Sildenafil has also been used in selected patients with PH due to selected cases of chronic respiratory disease without worsening oxygenation or SVR. A single dose of 50 mg nasogastric sildenafil has been studied in a small cohort of consecutive ARDS patients, lowering MAP, and worsening oxygenation due to increased V/Q mismatch, although RV performance did improve. Intravenous sildenafil has been shown to reduce SVR and PVR in end-stage congestive heart failure patients, although it is not available commercially, and its use is not licensed in unstable patients (Table 6).

GRADE RECOMMENDATION 7

46Based on mostly moderate-quality evidence (see Additional file 1), the following STRONG recommendation is made: pulmonary vasodilators reduce PVR, improve CO and oxygenation, and may be useful when PH and RV dysfunction are present, notably after cardiac surgery.

47Based on mostly moderate-quality evidence (see Additional file 1), the ICU side-effect profile of intravenous pulmonary vasodilators may be less favorable than that of inhaled agents. The following STRONG recommendation is therefore made: Consideration should be given to the use of inhaled rather than systemic agents when systemic hypotension is likely, and concomitant vasopressor use should be anticipated.

48Based on mostly high-quality evidence (see Additional file 1), the following STRONG recommendation is made: give consideration for the use of NO as a short-term therapy to improve oxygenation indices but not outcome in patients with ARDS. Based on low-quality evidence (see Additional file 1), a WEAK recommendation is made that pulmonary vasodilators may also be useful treat PH associated with RV dysfunction in ARDS.

49Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Oral sildenafil may reduce PVR and facilitate weaning from NO after cardiac surgery in selected patients with PH, without adverse effects on systemic blood pressure in well-selected patients.

Nonpharmacologic Management

50This encompasses RV "protective" strategies to avoid factors (Table 3) that may further increase PVR. Mechanical devices are also increasingly used to give a failing RV a bridge to recovery or transplantation.

Ventilatory strategies

51Important variables that may reduce pulmonary blood flow during ventilation include hypoxia, hypercapnia, and compression of the pulmonary vasculature at the extremes of lung volumes (Figure 4). Acute hypoxia leading to hypoxic pulmonary vasoconstriction is well described and may be augmented by many factors, including acidosis. Acute hypercapnia also leads to pulmonary vasoconstriction, although this may be attenuated with NO, and, when associated with high PEEP, leads to RV dilatation and reduced cardiac output in severe ARDS. A reduction in pulmonary blood flow occurs both at low volumes, such as in areas of atelectasis, and at high lung volumes, such as with increased airway plateau pressure (Pplat): Increased RV afterload, reduced venous return, and acute RV dysfunction may result. Both atelectasis and ventilation at high lung volumes should therefore be avoided in patients with RV dysfunction.

52Before the era of protective ventilatory strategies in ARDS, the incidence of acute RV failure was 60% and has since decreased to 10% to 25%. This is thought to reflect the change in ventilatory practice: lower Pplat reduces the incidence of RV failure. Prone ventilation may also reduce Pplat and pCO2 sufficiently to improve acute RV failure. In ARDS, transition to high-frequency oscillation leads to an increase in CVP and a minor decrease in cardiac output due to preload reduction, and RV function may decrease during recruitment maneuvers. In children after Fontan procedures, the hemodynamic effects of negative-pressure ventilation (NPV) are nicely illustrated by measuring pulmonary blood flow: after a switch from conventional intermittent positive pressure ventilation (IPPV) to NPV by using cuirass ventilation, pulmonary blood flow, stroke volume, and cardiac output increased up to 50%, and decreased to baseline when IPPV was reinstituted.

Mechanical support

53Mechanical support for the RV may be appropriate in reversible settings or as a bridge to definitive treatment. RV-assist devices (RVADs) may be used in primary RV dysfunction and have been used with coexisting PH. There is, however, concern that pulsatile devices may cause pulmonary microcirculatory damage in PH. A pumpless "lung assist" device has been used in patients bridging to transplant. Extracorporeal membrane oxygenation (ECMO) has been used in severe PH, as a bridge to transplant, and after endarterectomy or massive PE. Intraaortic balloon counterpulsation (IABP) has been used for RV failure after CPB and transplantation, thought to improve CO by augmenting left coronary flow rather than by direct RV effects. Atrial septostomy creates a right-to-left shunt that improves left atrial filling and LV function while reducing RV end-diastolic pressure and improving RV contractility. It is sometimes used as a bridge to transplantation in severe PAH, although not in patients with very severe RV failure.

GRADE RECOMMENDATION 8

54Based on mostly very-low-quality evidence, the following WEAK recommendation is made: Mechanical therapies including ECMO and IABP may have a role as rescue therapies in reversible pulmonary vascular dysfunction or while awaiting definitive treatment.

Conclusions

55Pulmonary vascular and right ventricular dysfunction may complicate many ICU illnesses: the diagnosis may be difficult, and the acute management, challenging. Their presence is associated with a worse outcome. This review highlights that some recommendations can be made, despite limitations of the GRADE analysis. However, we do consider that "weak GRADE recommendations" could be interpreted as "management suggestions" and treated with appropriate caution. A further limitation is that several pathologies have been grouped together as one syndrome, although this relates to both the rarity of the syndrome and the lack of high-quality evidence: further research is desperately needed. In particular, only then will we learn whether PAH-targeted therapy such as use of PDE5 inhibitors or endothelin-receptor antagonists, so effective in idiopathic PAH, have a role in the ICU setting.

Key messages

56• Pulmonary hypertension (PH) and associated right ventricular (RV) failure are associated with worse outcomes in critical care, and because of nonspecific presenting symptoms and signs, may be difficult to recognize: echocardiography is a very useful initial test, and invasive monitoring may be helpful in some cases for more continuous monitoring and accurate measurement of pulmonary vascular resistance.

57• Volume loading of the right ventricle may worsen its performance: all fluid challenges should be closely monitored.

58• It is essential to maintain adequate aortic root pressure to prevent the onset of RV ischemia. Vasopressors are useful in this setting, including low-dose norepinephrine as a first-line agent. Low-dose vasopressin may also be useful in some resistant cases but has adverse myocardial effects at higher doses. Potentially useful inotropes in RV failure include dobutamine and those with additional pulmonary vasodilating effects, including PDE III inhibitors, although co-administration with pressors is often necessary. The effects of any vasoactive drug may be unpredictable in an individual and require close clinical observation of circulatory performance, potentially assisted by echocardiography.

59• Pulmonary vasodilators are useful to reduce RV afterload in several ICU settings, including PH and RV failure after cardiac surgery. Systemic administration may worsen systemic hemodynamics and oxygenation because of ventilation-perfusion mismatching.

60• The use of mechanical therapies to manage acute PH and enhance RV performance is expanding, although with evidence currently limited to case series, and may be useful in experienced centers to ameliorate RV failure while awaiting definitive therapy.

Abbreviations

61ACP: acute cor pulmonale; ARDS: acute respiratory distress syndrome; AVP: arginine vasopressin; cAMP: cyclic adenosine 3',5'-cyclic monophosphate; cGMP: cyclic guanosine 3',5'-cyclic monophosphate; CI: cardiac index; CO: cardiac output; COPD: chronic obstructive pulmonary disease; CPB: cardiopulmonary bypass; CVP: central venous pressure; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IABP: intraaortic balloon pump; LV: left ventricle; MVR: mitral valve replacement; NE: norepinephrine; NO: nitric oxide; PAC: pulmonary artery catheter; PAH: pulmonary arterial hypertension; PAOP: pulmonary arterial occlusion pressure; PDE: phosphodiesterase; PE: pulmonary embolism; PGE1: prostaglandin E1; PH: pulmonary hypertension; PHE: phenylephrine; PVR: pulmonary vascular resistance; RV: right ventricle; RVEF: right ventricular ejection fraction; RVF: right ventricular failure; SvO2: mixed venous oxygen saturation; SVR: systemic vascular resistance; TEE: transesophageal echocardiography; TR: tricuspid regurgitation; V/Q mismatch: ventilation/perfusion mismatch.

Competing interests

62LCP has received honoraria from Encysive Pharmaceuticals. SJW has received honoraria from Actelion Pharmaceuticals. SJB has received support for clinical trials from Pfizer, Astra Zeneca, and Baxter Healthcare.

Authors' contributions

63LCP and SJB conceived of the review and participated in its design. LCP and SJW carried out the literature search and drafted the initial manuscript. All authors read and approved the final manuscript.

References 365

1.
Snow RL Davies P Pontoppidan H Zapol WM Reid L Pulmonary vascular remodeling in adult respiratory distress syndromeAm Rev Respir Dis1982 126887892
Not in our library10.1164/arrd.1982.126.5.887
2.
Gillis CN Pitt BR Wiedemann HP Hammond GL Depressed prostaglandin E1 and 5-hydroxytryptamine removal in patients with adult respiratory distress syndromeAm Rev Respir Dis1986 134739744
Not in our library10.1164/arrd.1986.134.4.739
3.
Greene R Zapol WM Snider MT Reid L Snow R O'Connell RS Novelline RA Early bedside detection of pulmonary vascular occlusion during acute respiratory failureAm Rev Respir Dis1981 124593601
Not in our library10.1164/arrd.1981.124.5.593
4.
Piazza G Goldhaber SZ The acutely decompensated right ventricle: pathways for diagnosis and managementChest2005 12818361852
Not in our library10.1378/chest.128.3.1836
5.
Jacobs AK Leopold JA Bates E Mendes LA Sleeper LA White H Davidoff R Boland J Modur S Forman R Hochman JS Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registryJ Am Coll Cardiol2003 4112731279
Not in our library10.1016/s0735-1097(03)00120-7
6.
Kimchi A Ellrodt AG Berman DS Riedinger MS Swan HJ Murata GH Right ventricular performance in septic shock: a combined radionuclide and hemodynamic studyJ Am Coll Cardiol1984 4945951
Not in our library10.1016/s0735-1097(84)80055-8
7.
Parker MM McCarthy KE Ognibene FP Parrillo JE Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humansChest1990 97126131
Not in our library10.1378/chest.97.1.126
8.
Rubin LJ Primary pulmonary hypertensionN Engl J Med1997 336111117
Not in our library10.1056/nejm199701093360207
9.
Berger M Haimowitz A Van Tosh A Berdoff RL Goldberg E Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasoundJ Am Coll Cardiol1985 6359365
Not in our library10.1016/s0735-1097(85)80172-8
10.
Dabestani A Mahan G Gardin JM Takenaka K Burn C Allfie A Henry WL Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiographyAm J Cardiol1987 59662668
Not in our library10.1016/0002-9149(87)91189-1
11.
Bossone E Bodini BD Mazza A Allegra L Pulmonary arterial hypertension: the key role of echocardiographyChest2005 12718361843
Not in our library10.1378/chest.127.5.1836
12.
Forfia PR Fisher MR Mathai SC Housten-Harris T Hemnes AR Borlaug BA Chamera E Corretti MC Champion HC Abraham TP Girgis RE Hassoun PM Tricuspid annular displacement predicts survival in pulmonary hypertensionAm J Respir Crit Care Med2006 17410341041
Not in our library10.1164/rccm.200604-547oc
13.
Lang RM Bierig M Devereux RB Flachskampf FA Foster E Pellikka PA Picard MH Roman MJ Seward J Shanewise JS Solomon SD Spencer KT Sutton MS Stewart WJ Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of CardiologyJ Am Soc Echocardiogr2005 1814401463
Not in our library10.1016/j.echo.2005.10.005
14.
Le Tulzo Y Seguin P Gacouin A Camus C Suprin E Jouannic I Thomas R Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: a preliminary descriptive studyIntensive Care Med1997 23664670
Not in our library10.1007/s001340050391
15.
Vieillard-Baron A Prin S Chergui K Dubourg O Jardin F Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unitAm J Respir Crit Care Med2002 16613101319
Not in our library10.1164/rccm.200202-146cc
16.
Jardin F Dubourg O Bourdarias JP Echocardiographic pattern of acute cor pulmonaleChest1997 111209217
Not in our library10.1378/chest.111.1.209
17.
Fischer LG Van Aken H Burkle H Management of pulmonary hypertension: physiological and pharmacological considerations for anesthesiologistsAnesth Analg2003 9616031616
Not in our library10.1213/01.ane.0000062523.67426.0b
18.
Ocal A Kiris I Erdinc M Peker O Yavuz T Ibrisim E Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertensionTohoku J Exp Med2005 2075158
Not in our library10.1620/tjem.207.51
19.
Sibbald WJ Paterson NA Holliday RL Anderson RA Lobb TR Duff JH Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factorsChest1978 73583591
Not in our library10.1378/chest.73.5.583
20.
Wort SJ Evans TW The role of the endothelium in modulating vascular control in sepsis and related conditionsBr Med Bull1999 553048
Not in our library10.1258/0007142991902286
21.
Albertini M Clement MG Hussain SN Role of endothelin ETA receptors in sepsis-induced mortality, vascular leakage, and tissue injury in ratsEur J Pharmacol2003 474129135
Not in our library10.1016/s0014-2999(03)02037-5
22.
Rossi P Persson B Boels PJ Arner A Weitzberg E Oldner A Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constrictionIntensive Care Med2008 34873880
Not in our library10.1007/s00134-007-0980-9
23.
Osman D Monnet X Castelain V Anguel N Warszawski J Teboul JL Richard C Incidence and prognostic value of right ventricular failure in acute respiratory distress syndromeIntensive Care Med2009 356976
Not in our library10.1007/s00134-008-1307-1
24.
Vieillard-Baron A Schmitt JM Augarde R Fellahi JL Prin S Page B Beauchet A Jardin F Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosisCrit Care Med2001 2915511555
Not in our library10.1097/00003246-200108000-00009
25.
Vieillard-Baron A Page B Augarde R Prin S Qanadli S Beauchet A Dubourg O Jardin F Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rateIntensive Care Med2001 2714811486
Not in our library10.1007/s001340101032
26.
Ribeiro A Lindmarker P Juhlin-Dannfelt A Johnsson H Jorfeldt L Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rateAm Heart J1997 134479487
Not in our library10.1016/s0002-8703(97)70085-1
27.
Kasper W Konstantinides S Geibel A Tiede N Krause T Just H Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolismHeart1997 77346349
Not in our library10.1136/hrt.77.4.346
28.
Clowes GH Jr Farrington GH Zuschneid W Cossette GR Saravis C Circulating factors in the etiology of pulmonary insufficiency and right heart failure accompanying severe sepsis (peritonitis)Ann Surg1970 171663678
Not in our library10.1097/00000658-197005000-00005
29.
Monchi M Bellenfant F Cariou A Joly LM Thebert D Laurent I Dhainaut JF Brunet F Early predictive factors of survival in the acute respiratory distress syndrome: a multivariate analysisAm J Respir Crit Care Med1998 15810761081
Not in our library10.1164/ajrccm.158.4.9802009
30.
Squara P Dhainaut JF Artigas A Carlet J Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS StudyIntensive Care Med1998 2410181028
Not in our library10.1007/s001340050710
31.
Leeman M Pulmonary hypertension in acute respiratory distress syndromeMonaldi Arch Chest Dis1999 54146149
Not in our library
32.
Ramakrishna G Sprung J Ravi BS Chandrasekaran K McGoon MD Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortalityJ Am Coll Cardiol2005 4516911699
Not in our library10.1016/j.jacc.2005.02.055
33.
Minai OA Venkateshiah SB Arroliga AC Surgical intervention in patients with moderate to severe pulmonary arterial hypertensionConn Med2006 70239243
Not in our library
34.
Lai HC Lai HC Wang KY Lee WL Ting CT Liu TJ Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgeryBr J Anaesth2007 99184190
Not in our library10.1093/bja/aem126
35.
Krowka MJ Plevak DJ Findlay JY Rosen CB Wiesner RH Krom RA Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantationLiver Transpl2000 6443450
Not in our library10.1053/jlts.2000.6356
36.
Price LC Montani D Jais X Dick JR Simonneau G Sitbon O Mercier FJ Humbert M Non-cardiothoracic non-obstetric surgery in mild-moderate pulmonary hypertension: perioperative management of 28 consecutive individual casesEur Respir J2010 3512941302
Not in our library10.1183/09031936.00113009
37.
Bonnin M Mercier FJ Sitbon O Roger-Christoph S Jais X Humbert M Audibert F Frydman R Simonneau G Benhamou D Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive casesAnesthesiology2005 10211331137discussion 1135A-1136A
Not in our library10.1097/00000542-200506000-00012
38.
Bedard E Dimopoulos K Gatzoulis MA Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?Eur Heart J2009 30256265
Not in our library10.1093/eurheartj/ehn597
39.
Bernstein AD Parsonnet V Bedside estimation of risk as an aid for decision-making in cardiac surgeryAnn Thorac Surg2000 69823828
Not in our library10.1016/s0003-4975(99)01424-1
40.
Subramaniam K Yared JP Management of pulmonary hypertension in the operating roomSemin Cardiothorac Vasc Anesth2007 11119136
Not in our library10.1177/1089253207301733
41.
Morgan JA John R Lee BJ Oz MC Naka Y Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortalityAnn Thorac Surg2004 77859863
Not in our library10.1016/j.athoracsur.2003.09.048
42.
Price LC Montani D Jais X Dick JR Simonneau G Sitbon O Mercier FJ Humbert M Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertensionEur Respir J3512941302
Not in our library10.1183/09031936.00113009
43.
McIntyre KM Sasahara AA Determinants of right ventricular function and hemodynamics after pulmonary embolismChest1974 65534543
Not in our library10.1378/chest.65.5.534
44.
Kerbaul F Rondelet B Motte S Fesler P Hubloue I Ewalenko P Naeije R Brimioulle S Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failureCrit Care Med2004 3210351040
Not in our library10.1097/01.ccm.0000120052.77953.07
45.
Nath J Foster E Heidenreich PA Impact of tricuspid regurgitation on long-term survivalJ Am Coll Cardiol2004 43405409
Not in our library10.1016/j.jacc.2003.09.036
46.
Pinsky MR Heart-lung interactionsCurr Opin Crit Care2007 13528531
Not in our library10.1097/mcc.0b013e3282efad97
47.
Sibbald WJ Driedger AA Right ventricular function in acute disease states: pathophysiologic considerationsCrit Care Med1983 11339345
Not in our library10.1097/00003246-198305000-00004
48.
Pinsky MR Recent advances in the clinical application of heart-lung interactionsCurr Opin Crit Care2002 82631
Not in our library10.1097/00075198-200202000-00005
49.
Stojnic BB Brecker SJ Xiao HB Helmy SM Mbaissouroum M Gibson DG Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interactionBr Heart J1992 681620
Not in our library10.1136/hrt.68.7.16
50.
Taylor RR Covell JW Sonnenblick EH Ross J Dependence of ventricular distensibility on filling of the opposite ventricleAm J Physiol1967 213711718
Not in our library10.1152/ajplegacy.1967.213.3.711
51.
Fellahi JL Valtier B Beauchet A Bourdarias JP Jardin F Does positive end-expiratory pressure ventilation improve left ventricular function? A comparative study by transesophageal echocardiography in cardiac and noncardiac patientsChest1998 114556562
Not in our library10.1378/chest.114.2.556
52.
Louie EK Lin SS Reynertson SI Brundage BH Levitsky S Rich S Pressure and volume loading of the right ventricle have opposite effects on left ventricular ejection fractionCirculation1995 92819824
Not in our library10.1161/01.cir.92.4.819
53.
Louie EK Rich S Brundage BH Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertensionJ Am Coll Cardiol1986 812981306
Not in our library10.1016/s0735-1097(86)80300-x
54.
Ricciardi MJ Bossone E Bach DS Armstrong WF Rubenfire M Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowingChest1999 11612181223
Not in our library10.1378/chest.116.5.1218
55.
Vlahakes GJ Turley K Hoffman JI The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlationsCirculation1981 638795
Not in our library10.1161/01.cir.63.1.87
56.
Weitzenblum E Chronic cor pulmonaleHeart2003 89225230
Not in our library10.1136/heart.89.2.225
57.
Blaise G Langleben D Hubert B Pulmonary arterial hypertension: pathophysiology and anesthetic approachAnesthesiology2003 9914151432
Not in our library10.1097/00000542-200312000-00027
58.
Chin KM Kim NH Rubin LJ The right ventricle in pulmonary hypertensionCoron Artery Dis2005 161318
Not in our library10.1097/00019501-200502000-00003
59.
Hadian M Pinsky MR Evidence-based review of the use of the pulmonary artery catheter impact data and complicationsCrit Care2006 10 Suppl 3S8
Not in our library10.1186/cc4834
60.
Handa F Kyo SE Miyao H Reduction in the use of pulmonary artery catheter for cardiovascular surgeryMasui2003 52420423
Not in our library
61.
Mebazaa A Pitsis AA Rudiger A Toller W Longrois D Ricksten SE Bobek I De Hert S Wieselthaler G Schirmer U von Segesser LK Sander M Poldermans D Ranucci M Karpati PC Wouters P Seeberger M Schmid ER Weder W Follath F Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgeryCrit Care2010 14201
Not in our library10.1186/cc8153
62.
Zapol WM Kobayashi K Snider MT Greene R Laver MB Vascular obstruction causes pulmonary hypertension in severe acute respiratory failureChest1977 71306307
Not in our library10.1378/chest.71.2_supplement.306
63.
Vieillard-Baron A Assessment of right ventricular functionCurr Opin Crit Care2009 15254260
Not in our library10.1097/mcc.0b013e32832b70c9
64.
Gadhinglajkar S Sreedhar R Jayakumar K Misra M Ganesh S Panicker V Intra-operative assessment of biventricular function using trans-esophageal echocardiography pre/post-pulmonary thromboembolectomy in patient with chronic thromboembolic pulmonary hypertensionAnn Card Anaesth2009 12140145
Not in our library10.4103/0971-9784.53449
65.
Serra E Feltracco P Barbieri S Forti A Ori C Transesophageal echocardiography during lung transplantationTransplant Proc2007 3919811982
Not in our library10.1016/j.transproceed.2007.05.004
66.
Currie PJ Seward JB Chan KL Fyfe DA Hagler DJ Mair DD Reeder GS Nishimura RA Tajik AJ Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patientsJ Am Coll Cardiol1985 6750756
Not in our library10.1016/s0735-1097(85)80477-0
67.
Yock PG Popp RL Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitationCirculation1984 70657662
Not in our library10.1161/01.cir.70.4.657
68.
Nagaya N Nishikimi T Uematsu M Satoh T Kyotani S Sakamaki F Kakishita M Fukushima K Okano Y Nakanishi N Miyatake K Kangawa K Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertensionCirculation2000 102865870
Not in our library10.1161/01.cir.102.8.865
69.
Logeart D Lecuyer L Thabut G Tabet JY Tartiere JM Chavelas C Bonnin F Stievenart JL Solal AC Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolismIntensive Care Med2007 33286292
Not in our library10.1007/s00134-006-0482-1
70.
Lega JC Lacasse Y Lakhal L Provencher S Natriuretic peptides and troponins in pulmonary embolism: a meta-analysisThorax2009 64869875
Not in our library10.1136/thx.2008.110965
71.
Mehta NJ Jani K Khan IA Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolismAm Heart J2003 145821825
Not in our library10.1016/s0002-8703(02)94704-6
72.
Clark BJ Brown NJ Moss M Bull TM Increased serum BNP concentrations are associated with pulmonary vascular dysfunction in patients with acute lung injuryAm J Respir Crit Care Med2010 181A2582
Not in our library10.1164/rccm.201002-0250oc
73.
Alpert JS Smith R Carlson J Ockene IS Dexter L Dalen JE Mortality in patients treated for pulmonary embolismJAMA1976 23614771480
Not in our library10.1001/jama.236.13.1477
74.
Goldhaber SZ Haire WD Feldstein ML Miller M Toltzis R Smith JL Taveira da Silva AM Come PC Lee RT Parker JA Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusionLancet1993 341507511
Not in our library10.1016/0140-6736(93)90274-k
75.
Goldhaber SZ Morpurgo M Diagnosis, treatment, and prevention of pulmonary embolism: report of the WHO/International Society and Federation of Cardiology Task ForceJAMA1992 26817271733
Not in our library10.1001/jama.268.13.1727
76.
Pengo V Lensing AW Prins MH Marchiori A Davidson BL Tiozzo F Albanese P Biasiolo A Pegoraro C Iliceto S Prandoni P Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolismN Engl J Med2004 35022572264
Not in our library10.1056/nejmoa032274
77.
Dalen JE Alpert JS Natural history of pulmonary embolismProg Cardiovasc Dis1975 17259270
Not in our library10.1016/s0033-0620(75)80017-x
78.
Lualdi JC Goldhaber SZ Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors detection, and therapeutic implicationsAm Heart J1995 13012761282
Not in our library10.1016/0002-8703(95)90155-8
79.
Bhorade S Christenson J O'Connor M Lavoie A Pohlman A Hall JB Response to inhaled nitric oxide in patients with acute right heart syndromeAm J Respir Crit Care Med1999 159571579
Not in our library10.1164/ajrccm.159.2.9804127
80.
Guyatt GH Oxman AD Kunz R Vist GE Falck-Ytter Y Schunemann HJ What is "quality of evidence" and why is it important to clinicians?BMJ2008 336995998
Not in our library10.1136/bmj.39490.551019.be
81.
Guyatt GH Oxman AD Vist GE Kunz R Falck-Ytter Y Alonso-Coello P Schunemann HJ GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ2008 336924926
Not in our library10.1136/bmj.39489.470347.ad
82.
Gan CT Lankhaar JW Marcus JT Westerhof N Marques KM Bronzwaer JG Boonstra A Postmus PE Vonk-Noordegraaf A Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertensionAm J Physiol Heart Circ Physiol2006 290H1528H1533
Not in our library10.1152/ajpheart.01031.2005
83.
Zamanian RT Haddad F Doyle RL Weinacker AB Management strategies for patients with pulmonary hypertension in the intensive care unitCrit Care Med2007 3520372050
Not in our library10.1097/01.ccm.0000280433.74246.9e
84.
Reuse C Vincent JL Pinsky MR Measurements of right ventricular volumes during fluid challengeChest1990 9814501454
Not in our library10.1378/chest.98.6.1450
85.
Naeije R Vachiery JL Medical therapy of pulmonary hypertension conventional therapiesClin Chest Med2001 22517527
Not in our library10.1016/s0272-5231(05)70288-4
86.
Layish DT Tapson VF Pharmacologic hemodynamic support in massive pulmonary embolismChest1997 111218224
Not in our library10.1378/chest.111.1.218
87.
James KB Stelmach K Armstrong R Young JB Fouad-Tarazi F Plasma volume and outcome in pulmonary hypertensionTex Heart Inst J2003 30305307
Not in our library
88.
Mathru M Venus B Smith RA Shirakawa Y Sugiura A Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goatsCrit Care Med1986 14120124
Not in our library10.1097/00003246-198602000-00008
89.
Molloy WD Lee KY Girling L Schick U Prewitt RM Treatment of shock in a canine model of pulmonary embolismAm Rev Respir Dis1984 130870874
Not in our library10.1164/arrd.1984.130.5.870
90.
Ghignone M Girling L Prewitt RM Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogsAnesthesiology1984 60132135
Not in our library10.1097/00000542-198402000-00009
91.
Belenkie I Dani R Smith ER Tyberg JV Effects of volume loading during experimental acute pulmonary embolismCirculation1989 80178188
Not in our library10.1161/01.cir.80.1.178
92.
Mercat A Diehl JL Meyer G Teboul JL Sors H Hemodynamic effects of fluid loading in acute massive pulmonary embolismCrit Care Med1999 27540544
Not in our library10.1097/00003246-199903000-00032
93.
Redl G Germann P Plattner H Hammerle A Right ventricular function in early septic shock statesIntensive Care Med1993 1937
Not in our library10.1007/bf01709270
94.
Schneider AJ Teule GJ Groeneveld AB Nauta J Heidendal GA Thijs LG Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide studyAm Heart J1988 116103112
Not in our library10.1016/0002-8703(88)90256-6
95.
Siva A Shah AM Moderate mitral stenosis in pregnancy: the haemodynamic impact of diuresisHeart2005 91e3
Not in our library10.1136/hrt.2004.053017
96.
Ducas J Prewitt RM Pathophysiology and therapy of right ventricular dysfunction due to pulmonary embolismCardiovasc Clin1987 17191202
Not in our library
97.
Mebazaa A Karpati P Renaud E Algotsson L Acute right ventricular failure: from pathophysiology to new treatmentsIntensive Care Med2004 30185196
Not in our library10.1007/s00134-003-2025-3
98.
Goldhaber SZ The approach to massive pulmonary embolismSemin Respir Crit Care Med2000 21555561
Not in our library10.1055/s-2000-13184
99.
Forrest P Anaesthesia and right ventricular failureAnaesth Intensive Care2009 37370385
Not in our library10.1177/0310057x0903700314
100.
Kwak YL Lee CS Park YH Hong YW The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertensionAnaesthesia2002 57914
Not in our library10.1046/j.1365-2044.2002.02324.x
101.
Dunser MW Hasibeder WR Sympathetic overstimulation during critical illness: adverse effects of adrenergic stressJ Intensive Care Med2009 24293316
Not in our library10.1177/0885066609340519
102.
Bergofsky EH Humoral control of the pulmonary circulationAnnu Rev Physiol1980 42221233
Not in our library10.1146/annurev.ph.42.030180.001253
103.
Hanson EL O'Connor NE Drinker PA Hemodynamic response to controlled ventilation during hypoxia in man and animalsSurg Forum1972 23207209
Not in our library
104.
Tourneux P Rakza T Bouissou A Krim G Storme L Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertensionJ Pediatr2008 153345349
Not in our library10.1016/j.jpeds.2008.03.007
105.
Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study · 2009
No notice
106.
Schreuder WO Schneider AJ Groeneveld AB Thijs LG Effect of dopamine vs norepinephrine on hemodynamics in septic shock: emphasis on right ventricular performanceChest1989 9512821288
Not in our library10.1378/chest.95.6.1282
107.
Ducas J Duval D Dasilva H Boiteau P Prewitt RM Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristicsCirculation1987 75235242
Not in our library10.1161/01.cir.75.1.235
108.
Hirsch LJ Rooney MW Wat SS Kleinmann B Mathru M Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolismChest1991 100796801
Not in our library10.1378/chest.100.3.796
109.
Martin C Perrin G Saux P Papazian L Gouin F function Effects of norepinephrine on right ventricular in septic shock patientsIntensive Care Med1994 20444447
Not in our library10.1007/bf01710657
110.
Bertolissi M Bassi F Da Broi U Norepinephrine can be useful for the treatment of right ventricular failure combined with acute pulmonary hypertension and systemic hypotension: a case reportMinerva Anestesiol2001 677984
Not in our library
111.
Rich S Gubin S Hart K The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertensionChest1990 9811021106
Not in our library10.1378/chest.98.5.1102
112.
Eichinger MR Walker BR Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic ratsAm J Physiol1994 267H2413H2419
Not in our library10.1152/ajpheart.1994.267.6.h2413
113.
Walker BR Haynes J Jr Wang HL Voelkel NF Vasopressin-induced pulmonary vasodilation in ratsAm J Physiol1989 257H415H422
Not in our library10.1152/ajpheart.1989.257.2.h415
114.
Evora PR Pearson PJ Schaff HV Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxideChest1993 10312411245
Not in our library10.1378/chest.103.4.1241
115.
Jeon Y Ryu JH Lim YJ Kim CS Bahk JH Yoon SZ Choi JY Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patientsEur J Cardiothorac Surg2006 29952956
Not in our library10.1016/j.ejcts.2006.02.032
116.
Tayama E Ueda T Shojima T Akasu K Oda T Fukunaga S Akashi H Aoyagi S Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertensionInteract Cardiovasc Thorac Surg2007 6715719
Not in our library10.1510/icvts.2007.159624
117.
Braun EB Palin CA Hogue CW Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenolAnesth Analg2004 993637
Not in our library10.1213/01.ane.0000121349.15880.dc
118.
Price LC Forrest P Sodhi V Adamson DL Nelson-Piercy C Lucey M Howard LS Use of vasopressin after caesarean section in idiopathic pulmonary arterial hypertensionBr J Anaesth2007 99552555
Not in our library10.1093/bja/aem180
119.
Smith AM Elliot CM Kiely DG Channer KS The role of vasopressin in cardiorespiratory arrest and pulmonary hypertensionQJM2006 99127133
Not in our library10.1093/qjmed/hcl009
120.
Russell JA Walley KR Singer J Gordon AC Hebert PC Cooper DJ Holmes CL Mehta S Granton JT Storms MM Cook DJ Presneill JJ Ayers D Vasopressin versus norepinephrine infusion in patients with septic shockN Engl J Med2008 358877887
Not in our library10.1056/nejmoa067373
121.
Torgersen C Dunser MW Wenzel V Jochberger S Mayr V Schmittinger CA Lorenz I Schmid S Westphal M Grander W Luckner G Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trialIntensive Care Med2010 365765
Not in our library10.1007/s00134-009-1630-1
122.
Luckner G Mayr VD Jochberger S Wenzel V Ulmer H Hasibeder WR Dunser MW Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shockCrit Care Med2007 3522802285
Not in our library10.1097/01.ccm.0000281853.50661.23
123.
Gold J Cullinane S Chen J Seo S Oz MC Oliver JA Landry DW Vasopressin in the treatment of milrinone-induced hypotension in severe heart failureAm J Cardiol2000 85506508A511
Not in our library10.1016/s0002-9149(99)00783-3
124.
Argenziano M Choudhri AF Oz MC Rose EA Smith CR Landry DW A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placementCirculation1997 96II-286II-290
Not in our library
125.
Vida VL Mack R Castaneda AR The role of vasopressin in treating systemic inflammatory syndrome complicated by right ventricular failureCardiol Young2005 158890
Not in our library10.1017/s1047951105000193
126.
Scheurer MA Bradley SM Atz AM Vasopressin to attenuate pulmonary hypertension and improve systemic blood pressure after correction of obstructed total anomalous pulmonary venous returnJ Thorac Cardiovasc Surg2005 129464466
Not in our library10.1016/j.jtcvs.2004.06.043
127.
Wang HJ Wong CS Chiang CY Yeh CC Cherng CH Ho ST Wu CT Low-dose vasopressin infusion can be an alternative in treating patients with refractory septic shock combined with chronic pulmonary hypertension: a case reportActa Anaesthesiol Sin2003 417780
Not in our library
128.
Jain RL Horn EM Peripheral vasodilation complicated by pulmonary hypertension: a role for vasopressinAm J Respir Crit Care Med2008 177A919
Not in our library
129.
Holmes CL Walley KR Chittock DR Lehman T Russell JA The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case seriesIntensive Care Med2001 2714161421
Not in our library10.1007/s001340101014
130.
Dunser MW Mayr AJ Ulmer H Knotzer H Sumann G Pajk W Friesenecker B Hasibeder WR Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled studyCirculation2003 10723132319
Not in our library10.1161/01.cir.0000066692.71008.bb
131.
Dunser MW Mayr AJ Stallinger A Ulmer H Ritsch N Knotzer H Pajk W Mutz NJ Hasibeder WR Cardiac performance during vasopressin infusion in postcardiotomy shockIntensive Care Med2002 28746751
Not in our library10.1007/s00134-002-1265-y
132.
Lauzier F Levy B Lamarre P Lesur O Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trialIntensive Care Med2006 3217821789
Not in our library10.1007/s00134-006-0378-0
133.
Varma S Jaju BP Bhargava KP Mechanism of vasopressin-induced bradycardia in dogsCirc Res1969 24787792
Not in our library10.1161/01.res.24.6.787
134.
Naeije R Hallemans R Mols P Melot C Reding P Effect of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosisCrit Care Med1982 10578582
Not in our library10.1097/00003246-198209000-00004
135.
Mols P Hallemans R Van Kuyk M Melot C Lejeune P Ham H Vertongen F Naeije R Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertensionAnn Surg1984 199176181
Not in our library10.1097/00000658-198402000-00008
136.
Migotto WH Dahi H Effects of vasopressin on hemodynamics in cardiogenic shockChest2005 128168S
Not in our library
137.
Walker BR Childs ME Adams EM Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptorsAm J Physiol1988 255H261H265
Not in our library10.1152/ajpheart.1988.255.2.h261
138.
Leather HA Segers P Berends N Vandermeersch E Wouters PF Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertensionCrit Care Med2002 3025482552
Not in our library10.1097/00003246-200211000-00024
139.
Indrambarya T Boyd JH Wang Y McConechy M Walley KR Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in miceCrit Care2009 13R98
Not in our library10.1186/cc7930
140.
Tisdale JE Patel R Webb CR Borzak S Zarowitz BJ Electrophysiologic and proarrhythmic effects of intravenous inotropic agentsProg Cardiovasc Dis1995 38167180
Not in our library10.1016/s0033-0620(05)80005-2
141.
Holloway EL Polumbo RA Harrison DC Acute circulatory effects of dopamine in patients with pulmonary hypertensionBr Heart J1975 37482485
Not in our library10.1136/hrt.37.5.482
142.
Liet JM Boscher C Gras-Leguen C Gournay V Debillon T Roze JC Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosusJ Pediatr2002 140373375
Not in our library10.1067/mpd.2002.123100
143.
Leier CV Heban PT Huss P Bush CA Lewis RP Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failureCirculation1978 58466475
Not in our library10.1161/01.cir.58.3.466
144.
Lejeune P Naeije R Leeman M Melot C Deloof T Delcroix M Effects of dopamine and dobutamine on hyperoxic and hypoxic pulmonary vascular tone in dogsAm Rev Respir Dis1987 1362935
Not in our library10.1164/ajrccm/136.1.29
145.
Schreuder WO Schneider AJ Groeneveld AB Thijs LG The influence of catecholamines on right ventricular function in septic shockIntensive Care Med1988 14 Suppl 2492495
Not in our library10.1007/bf00256968
146.
De Backer D Biston P Devriendt J Madl C Chochrad D Aldecoa C Brasseur A Defrance P Gottignies P Vincent JL Comparison of dopamine and norepinephrine in the treatment of shockN Engl J Med2010 362779789
Not in our library10.1056/nejmoa0907118
147.
Barrington KJ Finer NN Chan WK A blind, randomized comparison of the circulatory effects of dopamine and epinephrine infusions in the newborn piglet during normoxia and hypoxiaCrit Care Med1995 23740748
Not in our library10.1097/00003246-199504000-00024
148.
Stobierska-Dzierzek B Awad H Michler RE The evolving management of acute right-sided heart failure in cardiac transplant recipientsJ Am Coll Cardiol2001 38923931
Not in our library10.1016/s0735-1097(01)01486-3
149.
Prielipp RC McLean R Rosenthal MH Pearl RG Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertensionCrit Care Med1991 196067
Not in our library10.1097/00003246-199101000-00016
150.
Acosta F Sansano T Palenciano CG Falcon L Domenech P Robles R Bueno FS Ramirez P Parrilla P Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantationTransplant Proc2005 3738693870
Not in our library10.1016/j.transproceed.2005.10.045
151.
Ferrario M Poli A Previtali M Lanzarini L Fetiveau R Diotallevi P Mussini A Montemartini C Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarctionAm J Cardiol1994 74329333
Not in our library10.1016/0002-9149(94)90398-0
152.
Sztrymf B Souza R Bertoletti L Jais X Sitbon O Price LC Simonneau G Humbert M Prognostic factors of acute heart failure in patients with pulmonary arterial hypertensionEur Respir J2010 3512861293
Not in our library10.1183/09031936.00070209
153.
Vizza CD Rocca GD Roma AD Iacoboni C Pierconti F Venuta F Rendina E Schmid G Pietropaoli P Fedele F Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertensionCrit Care2001 5355361
Not in our library10.1186/cc1069
154.
Pagnamenta A Fesler P Vandinivit A Brimioulle S Naeije R Pulmonary vascular effects of dobutamine in experimental pulmonary hypertensionCrit Care Med2003 3111401146
Not in our library10.1097/01.ccm.0000060126.75746.32
155.
Bradford KK Deb B Pearl RG Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbitJ Cardiovasc Pharmacol2000 36146151
Not in our library10.1097/00005344-200008000-00002
156.
Honerjager P Pharmacology of bipyridine phosphodiesterase III inhibitorsAm Heart J1991 12119391944
Not in our library10.1016/0002-8703(91)90828-6
157.
Young RA Ward A Milrinone. A preliminary review of its pharmacological properties and therapeutic useDrugs1988 36158192
Not in our library10.2165/00003495-198836020-00003
158.
Alousi AA Johnson DC Pharmacology of the bipyridines: amrinone and milrinoneCirculation1986 73III10III24
Not in our library
159.
Farah AE Frangakis CJ Studies on the mechanism of action of the bipyridine milrinone on the heartBasic Res Cardiol1989 84 Suppl 185103
Not in our library10.1007/bf02650349
160.
Oztekin I Yazici S Oztekin DS Goksel O Issever H Canik S Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertensionYakugaku Zasshi2007 127375383
Not in our library10.1248/yakushi.127.375
161.
Kihara S Kawai A Fukuda T Yamamoto N Aomi S Nishida H Endo M Koyanagi H Effects of milrinone for right ventricular failure after left ventricular assist device implantationHeart Vessels2002 166971
Not in our library10.1007/s380-002-8320-z
162.
Fukazawa K Poliac LC Pretto EA Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantationClin Transplant2010 24515519
Not in our library10.1111/j.1399-0012.2009.01119.x
163.
Harris MN Daborn AK O'Dwyer JP Milrinone and the pulmonary vascular systemEur J Anaesthesiol Suppl1992 52730
Not in our library
164.
Eichhorn EJ Konstam MA Weiland DS Roberts DJ Martin TT Stransky NB Salem DN Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathyAm J Cardiol1987 6013291333
Not in our library10.1016/0002-9149(87)90616-3
165.
Boldt J Knothe C Zickmann B Ballesteros M Russ W Dapper F Hempelmann G The role of enoximone in cardiac surgeryBr J Anaesth1992 694550
Not in our library10.1093/bja/69.1.45
166.
Tarr TJ Jeffrey RR Kent AP Cowen ME Use of enoximone in weaning from cardiopulmonary bypass following mitral valve surgeryCardiology1990 77 Suppl 35157discussion 62-67
Not in our library10.1159/000174672
167.
Leeman M Lejeune P Melot C Naeije R Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPDChest1987 91662666
Not in our library10.1378/chest.91.5.662
168.
Jenkins IR Dolman J O'Connor JP Ansley DM Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trialAnaesth Intensive Care1997 25245249
Not in our library10.1177/0310057x9702500306
169.
Dupuis JY Bondy R Cattran C Nathan HJ Wynands JE Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcomeJ Cardiothorac Vasc Anesth1992 6542553
Not in our library10.1016/1053-0770(92)90096-p
170.
Hachenberg T Mollhoff T Holst D Hammel D Brussel T Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertensionJ Cardiothorac Vasc Anesth1997 11453457
Not in our library10.1016/s1053-0770(97)90054-9
171.
Ansell J Tiarks C McCue J Parrilla N Benotti JR Amrinone-induced thrombocytopeniaArch Intern Med1984 144949952
Not in our library10.1001/archinte.144.5.949
172.
Boldt J Knothe C Zickmann B Herold C Dapper E Hempelmann G Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and functionIntensive Care Med1992 18449454
Not in our library10.1007/bf01708579
173.
Kikura M Lee MK Safon RA Bailey JM Levy JH The effects of milrinone on platelets in patients undergoing cardiac surgeryAnesth Analg1995 814448
Not in our library10.1097/00000539-199507000-00009
174.
Levy JH Bailey JM Deeb GM Intravenous milrinone in cardiac surgeryAnn Thorac Surg2002 73325330
Not in our library10.1016/s0003-4975(01)02719-9
175.
Chen EP Bittner HB Davis RD Jr Van Trigt P Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertensionAnn Thorac Surg1997 63814821
Not in our library10.1016/s0003-4975(97)00011-8
176.
Buckley MS Feldman JP Nebulized milrinone use in a pulmonary hypertensive crisisPharmacotherapy2007 2717631766
Not in our library10.1592/phco.27.12.1763
177.
Wang H Gong M Zhou B Dai A Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgeryAdv Ther2009 26462468
Not in our library10.1007/s12325-009-0019-4
178.
Haraldssons A Kieler-Jensen N Ricksten SE The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertensionAnesth Analg2001 9314391445table of contents
Not in our library10.1097/00000539-200112000-00018
179.
Sablotzki A Starzmann W Scheubel R Grond S Czeslick EG Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidatesCan J Anaesth2005 5210761082
Not in our library10.1007/bf03021608
180.
Follath F Cleland JG Just H Papp JG Scholz H Peuhkurinen K Harjola VP Mitrovic V Abdalla M Sandell EP Lehtonen L Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialLancet2002 360196202
Not in our library10.1016/s0140-6736(02)09455-2
181.
Barraud D Faivre V Damy T Welschbillig S Gayat E Heymes C Payen D Shah AM Mebazaa A Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinoneCrit Care Med2007 3513761382
Not in our library10.1097/01.ccm.0000261889.18102.84
182.
Ukkonen H Saraste M Akkila J Knuuti J Karanko M Iida H Lehikoinen P Nagren K Lehtonen L Voipio-Pulkki LM Myocardial efficiency during levosimendan infusion in congestive heart failureClin Pharmacol Ther2000 68522531
Not in our library10.1067/mcp.2000.110972
183.
Ukkonen H Saraste M Akkila J Knuuti MJ Lehikoinen P Nagren K Lehtonen L Voipio-Pulkki LM Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteersClin Pharmacol Ther1997 61596607
Not in our library10.1016/s0009-9236(97)90139-9
184.
Yildiz O Vasodilating mechanisms of levosimendan: involvement of K+ channelsJ Pharmacol Sci2007 10415
Not in our library10.1254/jphs.cp0060010
185.
Slawsky MT Colucci WS Gottlieb SS Greenberg BH Haeusslein E Hare J Hutchins S Leier CV LeJemtel TH Loh E Nicklas J Ogilby D Singh BN Smith W Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure: study investigatorsCirculation2000 10222222227
Not in our library10.1161/01.cir.102.18.2222
186.
Kivikko M Antila S Eha J Lehtonen L Pentikainen PJ Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failureInt J Clin Pharmacol Ther2002 40465471
Not in our library10.5414/cpp40465
187.
Leather HA Ver Eycken K Segers P Herijgers P Vandermeersch E Wouters PF Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigsCrit Care Med2003 3123392343
Not in our library10.1097/01.ccm.0000084844.95073.c0
188.
Kerbaul F Rondelet B Demester JP Fesler P Huez S Naeije R Brimioulle S Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failureCrit Care Med2006 3428142819
Not in our library10.1097/01.ccm.0000242157.19347.50
189.
Missant C Rex S Segers P Wouters PF Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunctionCrit Care Med2007 35707715
Not in our library10.1097/01.ccm.0000257326.96342.57
190.
Duygu H Ozerkan F Zoghi M Nalbantgil S Yildiz A Akilli A Akin M Nazli C Ergene O Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failureInt J Clin Pract2008 62228233
Not in our library10.1111/j.1742-1241.2007.01510.x
191.
Russ MA Prondzinsky R Carter JM Schlitt A Ebelt H Schmidt H Lemm H Heinroth K Soeffker G Winkler M Werdan K Buerke M Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendanCrit Care Med2009 3730173023
Not in our library10.1097/ccm.0b013e3181b0314a
192.
Yilmaz MB Yontar C Erdem A Karadas F Yalta K Turgut OO Yilmaz A Tandogan I Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failureHeart Vessels2009 241621
Not in our library10.1007/s00380-008-1077-2
193.
Poelzl G Zwick RH Grander W Metzler B Jonetzko P Frick M Ulmer H Pachinger O Roithinger FX Safety and effectiveness of levosimendan in patients with predominant right heart failureHerz2008 33368373
Not in our library10.1007/s00059-008-3051-2
194.
Parissis JT Paraskevaidis I Bistola V Farmakis D Panou F Kourea K Nikolaou M Filippatos G Kremastinos D Effects of levosimendan on right ventricular function in patients with advanced heart failureAm J Cardiol2006 9814891492
Not in our library10.1016/j.amjcard.2006.06.052
195.
Morelli A Teboul JL Maggiore SM Vieillard-Baron A Rocco M Conti G De Gaetano A Picchini U Orecchioni A Carbone I Tritapepe L Pietropaoli P Westphal M Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot studyCrit Care Med2006 3422872293
Not in our library10.1097/01.ccm.0000230244.17174.4f
196.
Morais RJ Levosimendan in severe right ventricular failure following mitral valve replacementJ Cardiothorac Vasc Anesth2006 208284
Not in our library10.1053/j.jvca.2005.01.039
197.
Cicekcioglu F Parlar AI Ersoy O Yay K Hijazi A Katircioglu SF Levosimendan and severe pulmonary hypertension during open heart surgeryGen Thorac Cardiovasc Surg2008 56563565
Not in our library10.1007/s11748-008-0301-4
198.
Kleber FX Bollmann T Borst MM Costard-Jackle A Ewert R Kivikko M Petterson T Pohjanjousi P Sonntag S Wikstrom G Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot studyJ Clin Pharmacol2009 49109115
Not in our library10.1177/0091270008325150
199.
Raper R FMM: The heart and circulation in sepsisBalliere's Clin Anaesthesiol1990 4333355
Not in our library10.1016/s0950-3501(05)80290-9
200.
Humbert M Sitbon O Simonneau G Treatment of pulmonary arterial hypertensionN Engl J Med2004 35114251436
Not in our library10.1056/nejmra040291
201.
Galie N Hoeper MM Humbert M Torbicki A Vachiery JL Barbera JA Beghetti M Corris P Gaine S Gibbs JS Gomez-Sanchez MA Jondeau G Klepetko W Opitz C Peacock A Rubin L Zellweger M Simonneau G Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)Eur Respir J2009 3412191263
Not in our library10.1183/09031936.00139009
202.
Kieler-Jensen N Lundin S Ricksten SE Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprussideJ Heart Lung Transplant1995 14436443
Not in our library
203.
Creagh-Brown BC Griffiths MJ Evans TW Bench-to-bedside review: inhaled nitric oxide therapy in adultsCrit Care2009 13221
Not in our library10.1186/cc7734
204.
McNeil K Dunning J Morrell NW The pulmonary physician in critical care, 13: the pulmonary circulation and right ventricular failure in the ITUThorax2003 58157162
Not in our library10.1136/thorax.58.2.157
205.
Channick RN Hoch RC Newhart JW Johnson FW Smith CM Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosisAm J Respir Crit Care Med1994 149811814
Not in our library10.1164/ajrccm.149.3.8118653
206.
Griffiths MJ Evans TW Inhaled nitric oxide therapy in adultsN Engl J Med2005 35326832695
Not in our library10.1056/nejmra051884
207.
Aranda M Bradford KK Pearl RG Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertensionAnesth Analg1999 89152158
Not in our library10.1097/00000539-199907000-00027
208.
Morgan JM McCormack DG Griffiths MJ Morgan CJ Barnes PJ Evans TW Adenosine as a vasodilator in primary pulmonary hypertensionCirculation1991 8411451149
Not in our library10.1161/01.cir.84.3.1145
209.
Fullerton DA Jones SD Grover FL McIntyre RC Jr Adenosine effectively controls pulmonary hypertension after cardiac operationsAnn Thorac Surg1996 6111181123discussion 1123-1114
Not in our library10.1016/0003-4975(95)01149-8
210.
Haywood GA Sneddon JF Bashir Y Jennison SH Gray HH McKenna WJ Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure: a good test but a poor therapyCirculation1992 86896902
Not in our library10.1161/01.cir.86.3.896
211.
Oliveira EC Ribeiro AL Amaral CF Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxideRespir Med104606611
Not in our library10.1016/j.rmed.2009.11.010
212.
Pepke-Zaba J Higenbottam TW Dinh-Xuan AT Stone D Wallwork J Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertensionLancet1991 33811731174
Not in our library10.1016/0140-6736(91)92033-x
213.
King R Esmail M Mahon S Dingley J Dwyer S Use of nitric oxide for decompensated right ventricular failure and circulatory shock after cardiac arrestBr J Anaesth2000 85628631
Not in our library10.1093/bja/85.4.628
214.
Frostell CG Blomqvist H Hedenstierna G Lundberg J Zapol WM Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilationAnesthesiology1993 78427435
Not in our library10.1097/00000542-199303000-00005
215.
Schenk P Mittermayer C Ratheiser K Inhaled nitric oxide in a patient with severe pulmonary embolismAnn Emerg Med1999 33710714
Not in our library
216.
Capellier G Jacques T Balvay P Blasco G Belle E Barale F Inhaled nitric oxide in patients with pulmonary embolismIntensive Care Med1997 2310891092
Not in our library10.1007/s001340050461
217.
Inglessis I Shin JT Lepore JJ Palacios IF Zapol WM Bloch KD Semigran MJ Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shockJ Am Coll Cardiol2004 44793798
Not in our library10.1016/j.jacc.2004.05.047
218.
Fujita Y Nishida O Sobue K Ito H Kusama N Inagaki M Katsuya H Nitric oxide inhalation is useful in the management of right ventricular failure caused by myocardial infarctionCrit Care Med2002 3013791381
Not in our library10.1097/00003246-200206000-00042
219.
Rich GF Murphy GD Jr Roos CM Johns RA Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patientsAnesthesiology1993 7810281035
Not in our library10.1097/00000542-199306000-00004
220.
Macdonald PS Keogh A Mundy J Rogers P Nicholson A Harrison G Jansz P Kaan AM Spratt P Adjunctive use of inhaled nitric oxide during implantation of a left ventricular assist deviceJ Heart Lung Transplant1998 17312316
Not in our library
221.
Beck JR Mongero LB Kroslowitz RM Choudhri AF Chen JM DeRose JJ Argenziano M Smerling AJ Oz MC Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgeryPerfusion1999 143742
Not in our library10.1177/026765919901400106
222.
Fernandez-Perez ER Keegan MT Harrison BA Inhaled nitric oxide for acute right-ventricular dysfunction after extrapleural pneumonectomyRespir Care2006 5111721176
Not in our library
223.
Fattouch K Sbraga F Bianco G Speziale G Gucciardo M Sampognaro R Ruvolo G Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacementJ Card Surg2005 20171176
Not in our library10.1111/j.0886-0440.2005.200383w.x
224.
Takaba K Aota M Nonaka M Sugimoto A Konishi Y Successful treatment of chronic thromboembolic pulmonary hypertension with inhaled nitric oxide after right ventricular thrombectomyJpn J Thorac Cardiovasc Surg2004 52257260
Not in our library10.1007/s11748-004-0120-1
225.
Maxey TS Smith CD Kern JA Tribble CG Jones DR Kron IL Crosby IK Beneficial effects of inhaled nitric oxide in adult cardiac surgical patientsAnn Thorac Surg2002 73529532discussion 532-523
Not in our library10.1016/s0003-4975(01)03398-7
226.
Khan TA Schnickel G Ross D Bastani S Laks H Esmailian F Marelli D Beygui R Shemin R Watson L Vartapetian I Ardehali A A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipientsJ Thorac Cardiovasc Surg2009 13814171424
Not in our library10.1016/j.jtcvs.2009.04.063
227.
Carrier M Blaise G Belisle S Perrault LP Pellerin M Petitclerc R Pelletier LC Nitric oxide inhalation in the treatment of primary graft failure following heart transplantationJ Heart Lung Transplant1999 18664667
Not in our library10.1016/s1053-2498(99)00025-x
228.
Trummer G Berchtold-Herz M Martin J Beyersdorf F Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomyAnn Thorac Surg2002 7312991301
Not in our library10.1016/s0003-4975(01)03265-9
229.
Yoshikawa T Date H Yamashita M Nagahiro I Aoe M Shimizu N Inhaled nitric oxide ameliorates postoperative acute graft dysfunction after living-donor lobar lung transplantationJpn J Thorac Cardiovasc Surg2000 48742745
Not in our library10.1007/bf03218245
230.
Girardis M Pasqualotto A Colo F Dal Pos L Sabbadini D Pasqualucci A Pasetto A Severe hypoxemia and pulmonary hypertension during orthotopic liver transplantation: a successful use of inhaled nitric oxideIntensive Care Med1999 25638
Not in our library10.1007/s001340050919
231.
Ralley FE The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administrationAnesth Analg1999 88505507
Not in our library10.1097/00000539-199903000-00007
232.
Williams TJ Salamonsen RF Snell G Kaye D Esmore DS Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantationJ Heart Lung Transplant1995 14419423
Not in our library
233.
Molmenti EP Ramsay M Ramsay K Lynch K Tillmann Hein HA Molmenti H Levy M Goldstein R Ausloos K East C Fasola C Jung G Escobar J Klintmalm G Epoprostenol and nitric oxide therapy for severe pulmonary hypertension in liver transplantationTransplant Proc2001 331332
Not in our library10.1016/s0041-1345(00)02807-4
234.
Snow DJ Gray SJ Ghosh S Foubert L Oduro A Higenbottam TW Wells FC Latimer RD Inhaled nitric oxide in patients with normal and increased pulmonary vascular resistance after cardiac surgeryBr J Anaesth1994 72185189
Not in our library10.1093/bja/72.2.185
235.
Bender KA Alexander JA Enos JM Skimming JW Effects of inhaled nitric oxide in patients with hypoxemia and pulmonary hypertension after cardiac surgeryAm J Crit Care1997 6127131
Not in our library
236.
Solina A Papp D Ginsberg S Krause T Grubb W Scholz P Pena LL Cody R A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patientsJ Cardiothorac Vasc Anesth2000 141217
Not in our library10.1016/s1053-0770(00)90048-x
237.
Solina AR Ginsberg SH Papp D Pantin EJ Denny J Ghandivel I Krause TJ Response to nitric oxide during adult cardiac surgeryJ Invest Surg2002 15514
Not in our library10.1080/08941930252807732
238.
Solina AR Ginsberg SH Papp D Grubb WR Scholz PM Pantin EJ Cody RP Krause TJ Dose response to nitric oxide in adult cardiac surgery patientsJ Clin Anesth2001 13281286
Not in our library10.1016/s0952-8180(01)00270-7
239.
Fattouch K Sbraga F Sampognaro R Bianco G Gucciardo M Lavalle C Vizza CD Fedele F Ruvolo G Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind studyJ Cardiovasc Med (Hagerstown)2006 7119123
Not in our library10.2459/01.jcm.0000203850.97890.fe
240.
Healy DG Veerasingam D McHale J Luke D Successful perioperative utilisation of inhaled nitric oxide in mitral valve surgeryJ Cardiovasc Surg (Torino)2006 47217220
Not in our library
241.
Rossaint R Falke KJ Lopez F Slama K Pison U Zapol WM Inhaled nitric oxide for the adult respiratory distress syndromeN Engl J Med1993 328399405
Not in our library10.1056/nejm199302113280605
242.
Fierobe L Brunet F Dhainaut JF Monchi M Belghith M Mira JP Dall'ava-Santucci J Dinh-Xuan AT Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndromeAm J Respir Crit Care Med1995 15114141419
Not in our library10.1164/ajrccm.151.5.7735594
243.
Romberg-Camps MJ Korsten HH Botman CJ Bindels AJ Roos AN Right ventricular failure in acute respiratory distress syndromeNeth J Med2000 579497
Not in our library10.1016/s0300-2977(00)00052-8
244.
Chiche JD Canivet JL Damas P Joris J Lamy M Inhaled nitric oxide for hemodynamic support after postpneumonectomy ARDSIntensive Care Med1995 21675678
Not in our library10.1007/bf01711547
245.
Benzing A Mols G Beyer U Geiger K Large increase in cardiac output in a patient with ARDS and acute right heart failure during inhalation of nitric oxideActa Anaesthesiol Scand1997 41643646
Not in our library10.1111/j.1399-6576.1997.tb04758.x
246.
Bigatello LM Hurford WE Kacmarek RM Roberts JD Jr Zapol WM Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome: effects on pulmonary hemodynamics and oxygenationAnesthesiology1994 80761770
Not in our library10.1097/00000542-199404000-00007
247.
Hsu CW Lee DL Lin SL Sun SF Chang HW The initial response to inhaled nitric oxide treatment for intensive care unit patients with acute respiratory distress syndromeRespiration2008 75288295
Not in our library10.1159/000101478
248.
Gerlach H Keh D Semmerow A Busch T Lewandowski K Pappert DM Rossaint R Falke KJ Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled studyAm J Respir Crit Care Med2003 16710081015
Not in our library10.1164/rccm.2108121
249.
Dellinger RP Zimmerman JL Taylor RW Straube RC Hauser DL Criner GJ Davis K Jr Hyers TM Papadakos P Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial: inhaled nitric oxide in ARDS study groupCrit Care Med1998 261523
Not in our library10.1097/00003246-199801000-00011
250.
Taylor RW Zimmerman JL Dellinger RP Straube RC Criner GJ Davis K Jr Kelly KM Smith TC Small RJ Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trialJAMA2004 29116031609
Not in our library10.1001/jama.291.13.1603
251.
Brett SJ Hansell DM Evans TW Clinical correlates in acute lung injury: response to inhaled nitric oxideChest1998 11413971404
Not in our library10.1378/chest.114.5.1397
252.
Manktelow C Bigatello LM Hess D Hurford WE Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndromeAnesthesiology1997 87297307
Not in our library10.1097/00000542-199708000-00017
253.
Adhikari NK Burns KE Friedrich JO Granton JT Cook DJ Meade MO Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysisBMJ2007 334779
Not in our library10.1136/bmj.39139.716794.55
254.
Sokol J Jacobs SE Bohn D Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysisAnesth Analg2003 97989998
Not in our library10.1213/01.ane.0000078819.48523.26
255.
Troncy E Collet JP Shapiro S Guimond JG Blair L Ducruet T Francoeur M Charbonneau M Blaise G Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled studyAm J Respir Crit Care Med1998 15714831488
Not in our library10.1164/ajrccm.157.5.9707090
256.
Michael JR Barton RG Saffle JR Mone M Markewitz BA Hillier K Elstad MR Campbell EJ Troyer BE Whatley RE Liou TG Samuelson WM Carveth HJ Hinson DM Morris SE Davis BL Day RW Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDSAm J Respir Crit Care Med1998 15713721380
Not in our library10.1164/ajrccm.157.5.96-10089
257.
Lundin S Mang H Smithies M Stenqvist O Frostell C Inhalation of nitric oxide in acute lung injury: results of a European multicentre study: the European Study Group of Inhaled Nitric OxideIntensive Care Med1999 25911919
Not in our library10.1007/s001340050982
258.
Vater Y Martay K Dembo G Bowdle TA Weinbroum AA Intraoperative epoprostenol and nitric oxide for severe pulmonary hypertension during orthotopic liver transplantation: a case report and review of the literatureMed Sci Monit2006 12CS115CS118
Not in our library
259.
Flondor M Merkel M Hofstetter C Irlbeck M Frey L Zwissler B The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomyAnaesthesia2006 6112001203
Not in our library10.1111/j.1365-2044.2006.04861.x
260.
Lepore JJ Maroo A Bigatello LM Dec GW Zapol WM Bloch KD Semigran MJ Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxideChest2005 12716471653
Not in our library10.1378/chest.127.5.1647
261.
Lepore JJ Maroo A Pereira NL Ginns LC Dec GW Zapol WM Bloch KD Semigran MJ Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertensionAm J Cardiol2002 90677680
Not in our library10.1016/s0002-9149(02)02586-9
262.
Lavoie A Hall JB Olson DM Wylam ME Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failureAm J Respir Crit Care Med1996 15319851987
Not in our library10.1164/ajrccm.153.6.8665066
263.
Atz AM Adatia I Wessel DL Rebound pulmonary hypertension after inhalation of nitric oxideAnn Thorac Surg1996 6217591764
Not in our library10.1016/s0003-4975(96)00542-5
264.
Christenson J Lavoie A O'Connor M Bhorade S Pohlman A Hall JB The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxideAm J Respir Crit Care Med2000 16114431449
Not in our library10.1164/ajrccm.161.5.9806138
265.
Giacomini M Borotto E Bosotti L Denkewitz T Reali-Forster C Carlucci P Centanni S Mantero A Iapichino G Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDSAnaesth Intensive Care2007 359193
Not in our library10.1177/0310057x0703500113
266.
Trachte AL Lobato EB Urdaneta F Hess PJ Klodell CT Martin TD Staples ED Beaver TM Oral sildenafil reduces pulmonary hypertension after cardiac surgeryAnn Thorac Surg2005 79194197discussion 194-197
Not in our library10.1016/j.athoracsur.2004.06.086
267.
Atz AM Wessel DL Sildenafil ameliorates effects of inhaled nitric oxide withdrawalAnesthesiology1999 91307310
Not in our library10.1097/00000542-199907000-00041
268.
Namachivayam P Theilen U Butt WW Cooper SM Penny DJ Shekerdemian LS Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in childrenAm J Respir Crit Care Med2006 17410421047
Not in our library10.1164/rccm.200605-694oc
269.
Klodell CT Jr Morey TE Lobato EB Aranda JM Jr Staples ED Schofield RS Hess PJ Martin TD Beaver TM Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devicesAnn Thorac Surg2007 836871discussion 71
Not in our library10.1016/j.athoracsur.2006.08.051
270.
Mychaskiw G Sachdev V Heath BJ Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist deviceJ Clin Anesth2001 13218220
Not in our library10.1016/s0952-8180(01)00252-5
271.
Moncada S Gryglewski RJ Bunting S Vane JR A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregationProstaglandins1976 12715737
Not in our library10.1016/0090-6980(76)90048-4
272.
Clapp LH Finney P Turcato S Tran S Rubin LJ Tinker A Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary arteryAm J Respir Cell Mol Biol2002 26194201
Not in our library10.1165/ajrcmb.26.2.4695
273.
Rubin LJ Mendoza J Hood M McGoon M Barst R Williams WB Diehl JH Crow J Long W Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trialAnn Intern Med1990 112485491
Not in our library10.7326/0003-4819-112-7-485
274.
Barst RJ Rubin LJ Long WA McGoon MD Rich S Badesch DB Groves BM Tapson VF Bourge RC Brundage BH Koerner SK Langleben D Keller CA Murali S Uretsky BF Clayton LM Jobsis MM Blackburn DS Shortino D Crow JW A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study GroupN Engl J Med1996 334296302
Not in our library10.1056/nejm199602013340504
275.
Olschewski H Simonneau G Galie N Higenbottam T Naeije R Rubin LJ Nikkho S Speich R Hoeper MM Behr J Winkler J Sitbon O Popov W Ghofrani HA Manes A Kiely DG Ewert R Meyer A Corris PA Delcroix M Gomez-Sanchez M Siedentop H Seeger W Inhaled iloprost for severe pulmonary hypertensionN Engl J Med2002 347322329
Not in our library10.1056/nejmoa020204
276.
Hoeper MM Schwarze M Ehlerding S Adler-Schuermeyer A Spiekerkoetter E Niedermeyer J Hamm M Fabel H Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogueN Engl J Med2000 34218661870
Not in our library10.1056/nejm200006223422503
277.
Hoeper MM Olschewski H Ghofrani HA Wilkens H Winkler J Borst MM Niedermeyer J Fabel H Seeger W A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study groupJ Am Coll Cardiol2000 35176182
Not in our library10.1016/s0735-1097(99)00494-5
278.
Olschewski H Ghofrani HA Walmrath D Temmesfeld-Wollbruck B Grimminger F Seeger W Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprostIntensive Care Med1998 24631634
Not in our library10.1007/s001340050628
279.
Sitbon O Humbert M Nunes H Parent F Garcia G Herve P Rainisio M Simonneau G Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol2002 40780788
Not in our library10.1016/s0735-1097(02)02012-0
280.
Kieler-Jensen N Milocco I Ricksten SE Pulmonary vasodilation after heart transplantation: a comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivityJ Heart Lung Transplant1993 12179184
Not in our library
281.
D'Ambra MN LaRaia PJ Philbin DM Watkins WD Hilgenberg AD Buckley MJ Prostaglandin E1: a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacementJ Thorac Cardiovasc Surg1985 89567572
Not in our library
282.
Vincent JL Carlier E Pinsky MR Goldstein J Naeije R Lejeune P Brimioulle S Leclerc JL Kahn RJ Primo G Prostaglandin E1 infusion for right ventricular failure after cardiac transplantationJ Thorac Cardiovasc Surg1992 1033339
Not in our library
283.
Radovancevic B Vrtovec B Thomas CD Croitoru M Myers TJ Radovancevic R Khan T Massin EK Frazier OH Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidatesJ Heart Lung Transplant2005 24690695
Not in our library10.1016/j.healun.2004.04.016
284.
Schmid ER Burki C Engel MH Schmidlin D Tornic M Seifert B Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgeryAnesth Analg1999 8911081115
Not in our library10.1097/00000539-199911000-00007
285.
Elliott CG Palevsky HI Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosisThorax2004 59536537
Not in our library10.1136/thx.2003.008193
286.
Haraldsson A Kieler-Jensen N Ricksten SE Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic studyJ Cardiothorac Vasc Anesth1996 10864868
Not in our library10.1016/s1053-0770(96)80047-4
287.
Hache M Denault AY Belisle S Couture P Babin D Tetrault F Guimond JG Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unitCan J Anaesth2001 48924929
Not in our library10.1007/bf03017361
288.
De Wet CJ Affleck DG Jacobsohn E Avidan MS Tymkew H Hill LL Zanaboni PB Moazami N Smith JR Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgeryJ Thorac Cardiovasc Surg2004 12710581067
Not in our library10.1016/j.jtcvs.2003.11.035
289.
Schroeder RA Wood GL Plotkin JS Kuo PC Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failureAnesth Analg2000 91291295
Not in our library10.1097/00000539-200008000-00008
290.
Lowson SM Doctor A Walsh BK Doorley PA Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgeryCrit Care Med2002 3027622764
Not in our library10.1097/00003246-200212000-00023
291.
Kramm T Eberle B Guth S Mayer E Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomyEur J Cardiothorac Surg2005 28882888
Not in our library10.1016/j.ejcts.2005.09.007
292.
Rex S Schaelte G Metzelder S Flier S de Waal EE Autschbach R Rossaint R Buhre W Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trialActa Anaesthesiol Scand2008 526572
Not in our library10.1111/j.1399-6576.2007.01476.x
293.
Yurtseven N Karaca P Uysal G Ozkul V Cimen S Tuygun AK Yuksek A Canik S A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgeryAnn Thorac Cardiovasc Surg2006 12319323
Not in our library
294.
Baysal A Bilsel S Bulbul OG Kayacioglu I Idiz M Yekeler I Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgeryHeart Surg Forum2006 9E536E542
Not in our library10.1532/hsf98.20051161
295.
Tissieres P Nicod L Barazzone-Argiroffo C Rimensberger PC Beghetti M Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertensionAnn Thorac Surg2004 78e4850
Not in our library10.1016/j.athoracsur.2003.12.096
296.
Sablotzki A Hentschel T Gruenig E Schubert S Friedrich I Muhling J Dehne MG Czeslick E Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistanceEur J Cardiothorac Surg2002 22746752
Not in our library10.1016/s1010-7940(02)00488-8
297.
Theodoraki K Rellia P Thanopoulos A Tsourelis L Zarkalis D Sfyrakis P Antoniou T Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypassCan J Anaesth2002 49963967
Not in our library10.1007/bf03016884
298.
Winterhalter M Simon A Fischer S Rahe-Meyer N Chamtzidou N Hecker H Zuk J Piepenbrock S Struber M Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trialJ Cardiothorac Vasc Anesth2008 22406413
Not in our library10.1053/j.jvca.2007.10.015
299.
Webb SA Stott S van Heerden PV The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolismIntensive Care Med1996 22353355
Not in our library10.1007/bf01700458
300.
Haraldsson A Kieler-Jensen N Wadenvik H Ricksten SE Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypassIntensive Care Med2000 26188194
Not in our library10.1007/s001340050044
301.
Radermacher P Santak B Wust HJ Tarnow J Falke KJ Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDSIntensive Care Med1990 16227232
Not in our library10.1007/bf01705156
302.
Zwissler B Kemming G Habler O Kleen M Merkel M Haller M Briegel J Welte M Peter K Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndromeAm J Respir Crit Care Med1996 15416711677
Not in our library10.1164/ajrccm.154.6.8970353
303.
van Heerden PV Barden A Michalopoulos N Bulsara MK Roberts BL Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDSChest2000 117819827
Not in our library10.1378/chest.117.3.819
304.
Walmrath D Schneider T Pilch J Grimminger F Seeger W Aerosolised prostacyclin in adult respiratory distress syndromeLancet1993 342961962
Not in our library10.1016/0140-6736(93)92004-d
305.
Van Heerden PV Webb SA Hee G Corkeron M Thompson WR Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemiaAnaesth Intensive Care1996 248790
Not in our library10.1177/0310057x9602400115
306.
Meyer J Theilmeier G Van Aken H Bone HG Busse H Waurick R Hinder F Booke M Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failureAnesth Analg1998 86753758
Not in our library10.1097/00000539-199804000-00015
307.
Kuhlen R Walbert E Frankel P Thaden S Behrendt W Rossaint R Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndromeIntensive Care Med1999 25752754
Not in our library10.1007/s001340050941
308.
Prasad S Wilkinson J Gatzoulis MA Sildenafil in primary pulmonary hypertensionN Engl J Med2000 3431342
Not in our library10.1056/nejm200011023431814
309.
Preston IR Klinger JR Houtches J Nelson D Farber HW Hill NS Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertensionRespir Med2005 9915011510
Not in our library10.1016/j.rmed.2005.03.026
310.
Michelakis E Tymchak W Lien D Webster L Hashimoto K Archer S Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxideCirculation2002 10523982403
Not in our library10.1161/01.cir.0000016641.12984.dc
311.
Archer SL Michelakis ED Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertensionN Engl J Med2009 36118641871
Not in our library10.1056/nejmct0904473
312.
Giaid A Saleh D Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertensionN Engl J Med1995 333214221
Not in our library10.1056/nejm199507273330403
313.
Black SM Sanchez LS Mata-Greenwood E Bekker JM Steinhorn RH Fineman JR sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertensionAm J Physiol Lung Cell Mol Physiol2001 281L1051L1057
Not in our library10.1152/ajplung.2001.281.5.l1051
314.
Wharton J Strange JW Moller GM Growcott EJ Ren X Franklyn AP Phillips SC Wilkins MR Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cellsAm J Respir Crit Care Med2005 172105113
Not in our library10.1164/rccm.200411-1587oc
315.
Nagendran J Archer SL Soliman D Gurtu V Moudgil R Haromy A St Aubin C Webster L Rebeyka IM Ross DB Light PE Dyck JR Michelakis ED Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractilityCirculation2007 116238248
Not in our library10.1161/circulationaha.106.655266
316.
Packer M Vasodilator therapy for primary pulmonary hypertension: limitations and hazardsAnn Intern Med1985 103258270
Not in our library10.7326/0003-4819-103-2-258
317.
De Santo LS Mastroianni C Romano G Amarelli C Marra C Maiello C Galdieri N Della Corte A Cotrufo M Caianiello G Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patientsTransplant Proc2008 4020152018
Not in our library10.1016/j.transproceed.2008.05.055
318.
Shim JK Choi YS Oh YJ Kim DH Hong YW Kwak YL Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgeryJ Thorac Cardiovasc Surg2006 13214201425
Not in our library10.1016/j.jtcvs.2006.08.035
319.
Madden BP Sheth A Ho TB Park JE Kanagasabay RR Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgeryBr J Anaesth2004 93155156
Not in our library10.1093/bja/aeh571
320.
Fung E Fiscus RR Yim AP Angelini GD Arifi AA The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgeryChest2005 12830653073
Not in our library10.1378/chest.128.4.3065
321.
Aubin MC Laurendeau S Mommerot A Lamarche Y Denault A Carrier M Perrault LP Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypassJ Cardiovasc Pharmacol2008 511117
Not in our library10.1097/fjc.0b013e3181598279
322.
Ghofrani HA Wiedemann R Rose F Schermuly RT Olschewski H Weissmann N Gunther A Walmrath D Seeger W Grimminger F Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trialLancet2002 360895900
Not in our library10.1016/s0140-6736(02)11024-5
323.
Ng J Finney SJ Shulman R Bellingan GJ Singer M Glynne PA Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?Br J Anaesth2005 94774777
Not in our library10.1093/bja/aei114
324.
Cornet AD Hofstra JJ Swart EL Girbes AR Juffermans NP Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDSIntensive Care Med2010 36758764
Not in our library10.1007/s00134-010-1754-3
325.
Botha P Parry G Dark JH Macgowan GA Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibitionJ Heart Lung Transplant2009 28676682
Not in our library10.1016/j.healun.2009.04.013
326.
Moudgil R Michelakis ED Archer SL Hypoxic pulmonary vasoconstrictionJ Appl Physiol2005 98390403
Not in our library10.1152/japplphysiol.00733.2004
327.
Lejeune P Brimioulle S Leeman M Hallemans R Melot C Naeije R Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogsAnesthesiology1990 73256264
Not in our library10.1097/00000542-199008000-00012
328.
Balanos GM Talbot NP Dorrington KL Robbins PA Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiographyJ Appl Physiol2003 9415431551
Not in our library10.1152/japplphysiol.00890.2002
329.
Mekontso Dessap A Charron C Devaquet J Aboab J Jardin F Brochard L Vieillard-Baron A Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndromeIntensive Care Med2009 3518501858
Not in our library10.1007/s00134-009-1569-2
330.
Puybasset L Stewart T Rouby JJ Cluzel P Mourgeon E Belin MF Arthaud M Landault C Viars P Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndromeAnesthesiology1994 8012541267
Not in our library10.1097/00000542-199406000-00013
331.
Biondi JW Schulman DS Matthay RA Effects of mechanical ventilation on right and left ventricular functionClin Chest Med1988 95571
Not in our library
332.
Jardin F Gueret P Dubourg O Farcot JC Margairaz A Bourdarias JP Two-dimensional echocardiographic evaluation of right ventricular size and contractility in acute respiratory failureCrit Care Med1985 13952956
Not in our library10.1097/00003246-198511000-00035
333.
Jardin F Vieillard-Baron A Is there a safe plateau pressure in ARDS? The right heart only knowsIntensive Care Med2007 33444447
Not in our library10.1007/s00134-007-0552-z
334.
Vieillard-Baron A Rabiller A Chergui K Peyrouset O Page B Beauchet A Jardin F Prone position improves mechanics and alveolar ventilation in acute respiratory distress syndromeIntensive Care Med2005 31220226
Not in our library10.1007/s00134-004-2478-z
335.
David M von Bardeleben RS Weiler N Markstaller K Scholz A Karmrodt J Eberle B Cardiac function and haemodynamics during transition to high-frequency oscillatory ventilationEur J Anaesthesiol2004 21944952
Not in our library10.1017/s0265021504000328
336.
Gernoth C Wagner G Pelosi P Luecke T Respiratory and haemodynamic changes during decremental open lung positive end-expiratory pressure titration in patients with acute respiratory distress syndromeCrit Care2009 13R59
Not in our library10.1186/cc7786
337.
Shekerdemian LS Shore DF Lincoln C Bush A Redington AN Negative-pressure ventilation improves cardiac output after right heart surgeryCirculation1996 94II49II55
Not in our library
338.
Shekerdemian LS Bush A Shore DF Lincoln C Redington AN Cardiopulmonary interactions after Fontan operations: augmentation of cardiac output using negative pressure ventilationCirculation1997 9639343942
Not in our library10.1161/01.cir.96.11.3934
339.
Giesler GM Gomez JS Letsou G Vooletich M Smalling RW Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarctionCatheter Cardiovasc Interv2006 68263266
Not in our library10.1002/ccd.20846
340.
Fonger JD Borkon AM Baumgartner WA Achuff SC Augustine S Reitz BA Acute right ventricular failure following heart transplantation: improvement with prostaglandin E1 and right ventricular assistJ Heart Transplant1986 5317321
Not in our library
341.
Nagarsheth NP Pinney S Bassily-Marcus A Anyanwu A Friedman L Beilin Y Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolismAnesth Analg2008 107962964
Not in our library10.1213/ane.0b013e31817f10e8
342.
Berman M Tsui S Vuylsteke A Klein A Jenkins DP Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO?J Heart Lung Transplant2008 2711881189
Not in our library10.1016/j.healun.2008.07.017
343.
Keogh AM Mayer E Benza RL Corris P Dartevelle PG Frost AE Kim NH Lang IM Pepke-Zaba J Sandoval J Interventional and surgical modalities of treatment in pulmonary hypertensionJ Am Coll Cardiol2009 54S67S77
Not in our library10.1016/j.jacc.2009.04.016
344.
Strueber M Hoeper MM Fischer S Cypel M Warnecke G Gottlieb J Pierre A Welte T Haverich A Simon AR Keshavjee S Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist deviceAm J Transplant2009 9853857
Not in our library10.1111/j.1600-6143.2009.02549.x
345.
Felton TW McCormick BA Finfer SR Fisher MM Life-threatening pulmonary hypertension and right ventricular failure complicating calcium and phosphate replacement in the intensive care unitAnaesthesia2006 614953
Not in our library10.1111/j.1365-2044.2005.04381.x
346.
Satoh H Masuda Y Izuta S Yaku H Obara H Pregnant patient with primary pulmonary hypertension: general anesthesia and extracorporeal membrane oxygenation support for termination of pregnancyAnesthesiology2002 9716381640
Not in our library10.1097/00000542-200212000-00045
347.
Chan CY Chen YS Ko WJ Wang SS Chiu IS Lee YC Chu SH Extracorporeal membrane oxygenation support for single lung transplantation in a patient with primary pulmonary hypertensionJ Heart Lung Transplant1998 17325327
Not in our library
348.
Jones RL St Cyr JA Tornabene SP Lauber B Harken AH Reversible pulmonary hypertension secondary to mitral valvular disease as an indication for extracorporeal membrane oxygenationJ Cardiothorac Vasc Anesth1991 5494497
Not in our library10.1016/1053-0770(91)90126-e
349.
Gregoric ID Chandra D Myers TJ Scheinin SA Loyalka P Kar B Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertensionJ Heart Lung Transplant2008 27466468
Not in our library10.1016/j.healun.2008.01.016
350.
Hsu HH Ko WJ Chen JS Lin CH Kuo SW Huang SC Lee YC Extracorporeal membrane oxygenation in pulmonary crisis and primary graft dysfunctionJ Heart Lung Transplant2008 27233237
Not in our library10.1016/j.healun.2007.11.570
351.
Berman M Tsui S Vuylsteke A Snell A Colah S Latimer R Hall R Arrowsmith JE Kneeshaw J Klein AA Jenkins DP Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomyAnn Thorac Surg2008 8612611267
Not in our library10.1016/j.athoracsur.2008.06.037
352.
Deehring R Kiss AB Garrett A Hillier AG Extracorporeal membrane oxygenation as a bridge to surgical embolectomy in acute fulminant pulmonary embolismAm J Emerg Med2006 24879880
Not in our library10.1016/j.ajem.2006.03.009
353.
Haller I Kofler A Lederer W Chemelli A Wiedermann FJ Acute pulmonary artery embolism during transcatheter embolization: successful resuscitation with veno-arterial extracorporeal membrane oxygenationAnesth Analg2008 107945947
Not in our library10.1213/ane.0b013e31817f91d8
354.
Szocik J Rudich S Csete M ECMO resuscitation after massive pulmonary embolism during liver transplantationAnesthesiology2002 97763764
Not in our library10.1097/00000542-200209000-00059
355.
Arlt M Philipp A Iesalnieks I Kobuch R Graf BM Successful use of a new hand-held ECMO system in cardiopulmonary failure and bleeding shock after thrombolysis in massive post-partal pulmonary embolismPerfusion2009 244950
Not in our library10.1177/0267659109106295
356.
Gold JP Shemin RJ DiSesa VJ Cohn L Collins JJ Jr Balloon pump support of the failing right heartClin Cardiol1985 8599602
Not in our library10.1002/clc.4960081110
357.
Arafa OE Geiran OR Andersen K Fosse E Simonsen S Svennevig JL Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantationAnn Thorac Surg2000 7015871593
Not in our library10.1016/s0003-4975(00)01864-6
358.
Darrah WC Sharpe MD Guiraudon GM Neal A Intraaortic balloon counterpulsation improves right ventricular failure resulting from pressure overloadAnn Thorac Surg1997 6417181723discussion 1723-1714
Not in our library10.1016/s0003-4975(97)01102-8
359.
Rothman A Sklansky MS Lucas VW Kashani IA Shaughnessy RD Channick RN Auger WR Fedullo PF Smith CM Kriett JM Jamieson SW Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertensionAm J Cardiol1999 84682686
Not in our library10.1016/s0002-9149(99)00416-6
360.
Rich S Dodin E McLaughlin VV Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its applicationAm J Cardiol1997 80369371
Not in our library10.1016/s0002-9149(97)00370-6
361.
Druml W Steltzer H Waldhausl W Lenz K Hammerle A Vierhapper H Gasic S Wagner OF Endothelin-1 in adult respiratory distress syndromeAm Rev Respir Dis1993 14811691173
Not in our library10.1164/ajrccm/148.5.1169
362.
Lambermont B Ghuysen A Kolh P Tchana-Sato V Segers P Gerard P Morimont P Magis D Dogne JM Masereel B D'Orio V Effects of endotoxic shock on right ventricular systolic function and mechanical efficiencyCardiovasc Res2003 59412418
Not in our library10.1016/s0008-6363(03)00368-7
363.
Nuckton TJ Alonso JA Kallet RH Daniel BM Pittet JF Eisner MD Matthay MA Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndromeN Engl J Med2002 34612811286
Not in our library10.1056/nejmoa012835
364.
Marshall BE Marshall C Frasch F Hanson CW Role of hypoxic pulmonary vasoconstriction in pulmonary gas exchange and blood flow distribution. 1. Physiologic conceptsIntensive Care Med1994 20291297
Not in our library10.1007/bf01708968
365.
Tomashefski JF Jr Davies P Boggis C Greene R Zapol WM Reid LM The pulmonary vascular lesions of the adult respiratory distress syndromeAm J Pathol1983 112112126
Not in our library

Cited by papers we hold 2

Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome · 2021
Not checked
IABP: history-evolution-pathophysiology-indications: what we need to know · 2016
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.